[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 89 of about 89
1. Zhang X, Liang SX, Jia L, Chen N, Fadare O, Schwartz PE, Kong B, Zheng W: Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium. Am J Pathol; 2009 Jun;174(6):2000-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium.
  • Alteration of p53 is an early event in the development of endometrial serous carcinoma (ESC).
  • We have recently identified a group of benign-looking endometria with p53 overexpression, designated "p53 signatures."
  • The p53 signatures were specifically associated with ESC, frequently found in the benign-appearing endometrium adjacent to the ESC and only rarely in either the endometrium adjacent to endometrioid carcinomas or in non-cancerous uteri.
  • We concluded that p53 gene mutations apparently precede the morphological changes in affected endometrial cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):38-52 [17197896.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Opin Obstet Gynecol. 2008 Feb;20(1):20-5 [18197001.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2263-9 [18369088.001]
  • [Cites] J Surg Oncol. 2008 Sep 1;98(3):207-13 [18623110.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4311-4 [11389050.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):207-23 [15306933.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] J Otolaryngol. 1984 Feb;13(1):1-6 [6716542.001]
  • [Cites] Mod Pathol. 1990 Mar;3(2):120-8 [2326248.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10):965-73 [1928552.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):600-10 [1599038.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1507-14 [9414196.001]
  • [Cites] Genetics. 1998 Apr;148(4):1433-40 [9560363.001]
  • [Cites] Genetics. 1998 Apr;148(4):1483-90 [9560368.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1463-73 [9850172.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):579-82 [15721397.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • (PMID = 19435786.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023074
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2684165
  •  go-up   go-down


2. Pejić S, Todorović A, Stojiljković V, Cvetković D, Lucić N, Radojicić RM, Saicić ZS, Pajović SB: Superoxide dismutase and lipid hydroperoxides in blood and endometrial tissue of patients with benign, hyperplastic and malignant endometrium. An Acad Bras Cienc; 2008 Sep;80(3):515-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superoxide dismutase and lipid hydroperoxides in blood and endometrial tissue of patients with benign, hyperplastic and malignant endometrium.
  • The objective of the present study was to examine changes in activities and levels of copper/zinc superoxide dismutase (CuZnSOD) and lipid hydroperoxides (LOOH) in blood and endometrial tissue of patients diagnosed with uterine myoma, endometrial polypus, hyperplasia simplex, hyperplasia complex and adenocarcinoma endometrii.
  • Decrease of both SOD activity and level was found in endometrium of patients with hyperplasia simplex, hyperplasia complex and adenocarcinoma in comparison to women with polypus or myoma.
  • LOOH level was elevated in both tissues of patients with hyperplasia or adenocarcinoma in comparison to healthy subjects or patients with benign diagnosis.
  • [MeSH-major] Adenocarcinoma. Endometrial Hyperplasia. Endometrial Neoplasms. Leiomyoma. Lipid Peroxides / analysis. Superoxide Dismutase / analysis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Middle Aged. Polyps / blood. Polyps / enzymology. Uterine Neoplasms / blood. Uterine Neoplasms / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797802.001).
  • [ISSN] 0001-3765
  • [Journal-full-title] Anais da Academia Brasileira de Ciências
  • [ISO-abbreviation] An. Acad. Bras. Cienc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipid Peroxides; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


3. Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ: GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol; 2006 Nov;19(11):1429-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma.
  • Regulation of glucose transport facilitator expression has been demonstrated in endometrial tissue and endometrial adenocarcinoma.
  • The following experiments were conducted to quantify and localize the expression of GLUT1 and GLUT8 in benign endometrium and compare this expression to endometrial cancer.
  • Endometrial tissue samples were obtained from random hysterectomy specimens of patients with benign indications for surgery and endometrial cancer.
  • Endometrial samples from 65 women who had undergone hysterectomy were examined (n=38 benign, n=27 malignant).
  • A 44 and a 35.4 kDa immunoreacive species was demonstrated in endometrium and endometrial cancer for GLUT1 and GLUT8, respectively.
  • GLUT8 expression was increased in all tumor subtypes compared to atrophic endometrium (P<0.001).
  • Apical localization by GLUT1 and GLUT8 was demonstrated in endometrial glands.
  • GLUT1 and GLUT8 are expressed in both human endometrium and endometrial cancer.
  • There appears to be a step-wise progression in GLUT1 and GLUT8 expression as tumor histopathology worsens.
  • GLUT1 and GLUT8 may be important markers in tumor differentiation, as well as providing energy to rapidly dividing tumor cells.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Glucose Transport Proteins, Facilitative / analysis. Glucose Transporter Type 1 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892013.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK47425; United States / NHLBI NIH HHS / HL / HL58119
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transport Proteins, Facilitative; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; 0 / SLC2A8 protein, human
  •  go-up   go-down


Advertisement
4. Akbulut M, Zekioglu O, Terek MC, Ozdemir N: Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor. Arch Gynecol Obstet; 2008 Sep;278(3):283-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor.
  • OBJECTIVE: Adenofibroma is a form of mixed mesodermal tumor in which epithelial and stromal components are benign, and usually arises in the endometrium of postmenopausal women.
  • We report a case of lipoadenofibroma of the endometrium that appeared as an intracavitary mass, which is very unusual because endometrioid adenofibroma rarely contains mature adipose tissue, only the second such case described in detail.
  • CASE: An endometrial polypoid mass measuring 1,5 cm with maximum diameter was found incidentally during total abdominal hysterectomy for keratinizing large cell carcinoma of the cervix in a 60-year-old woman.
  • The endometrial polypoid mass was found to be a lipoadenofibroma composed predominantly of collagenated fibrous stroma populated by cystically dilated and occasionally crowded glands lined with proliferative endometrium, intermingled with abundant mature adipose tissue.
  • CONCLUSION: We suggest that uterine adenofibromas with lipomatous areas belong to the family of mixed tumor of Mullerian origin.
  • [MeSH-major] Adenofibroma / pathology. Endometrial Neoplasms / pathology. Mixed Tumor, Mullerian / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236054.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Rodríguez G, Bilbao C, Ramírez R, Falcón O, León L, Chirino R, Falcón O Jr, Díaz BP, Rivero JF, Perucho M, Díaz-Chico BN, Díaz-Chico JC: Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. Int J Cancer; 2006 Mar 15;118(6):1420-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer.
  • The endometrium contains ARs and the androgens have antiproliferative properties in cultured endometrial cancer (EC) cells.
  • Larger CAG repeats of the AR gene give rise to a weaker transcriptional activity and have been found to be associated with endometrial carcinogenesis.
  • To study that possibility, we have genotyped both CAG and GGN polymorphisms of the AR gene in tumor tissue genomic DNA from a series of 204 consecutive patients with EC, and analyzed the results with regard to the pathological features and clinical outcome of patients.
  • When the genotypes of both repeats coexisting in each tumor specimen were taken into consideration, the relationship between the SS-CAG genotype and early stage remained only in the presence of the SS-GGN genotype (43.9% vs 0%, p = 0.01).
  • Our data suggests that short CAG or GGN repeats of the AR gene are associated with a more benign condition of traditional prognostic variables in EC.
  • [MeSH-major] Endometrial Neoplasms / pathology. Polymorphism, Genetic. Receptors, Androgen / genetics. Trinucleotide Repeat Expansion / genetics. Trinucleotide Repeats / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16187285.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen
  •  go-up   go-down


6. Francz M: [The premalignant disease of the endometrium: endometrial intraepithelial neoplasia]. Magy Onkol; 2008 Mar;52(1):35-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The premalignant disease of the endometrium: endometrial intraepithelial neoplasia].
  • [Transliterated title] Az endometrium rákmegelozo állapota: endometrialis intraepithelialis neoplasia.
  • The WHO 1994 classification for endometrial hyperplasias is based on the morphologic features of the lesions.
  • Modern molecular data related to endometrial tumorigenesis and precise computerized morphometric analysis have identified the lesion that may be considered as a precursor of endometrioid adenocarcinoma.
  • By definition, this endometrial intraepithelial neoplasia (EIN) is a clonal proliferation of architecturally and cytologically altered endometrial glands which are prone to malignant transformation to endometrioid (type I) endometrial adenocarcinoma.
  • The morphometric basis of EIN diagnosis is the D-score (DS), which is a logical combination of three morphometric features that represent the glandular complexity, glandular volume and cytological alterations.
  • Hyperplasia cases that do not fit into the EIN categories are considered as benign or hormonal endometrial hyperplasia.
  • This is the theoretical basis of a new classification system in premalignant endometrial diseases.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrium / pathology. Precancerous Conditions / classification
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / therapy. PTEN Phosphohydrolase / analysis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403295.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 19
  •  go-up   go-down


7. Busmanis I, Ho TH, Tan SB, Khoo KS: p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium. Ann Acad Med Singapore; 2005 Aug;34(7):421-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium.
  • INTRODUCTION: Uterine papillary serous carcinoma (UPSC), a high-grade tumour, is known to be associated in some cases with an identifiable intraepithelial neoplasia (IEN) component.
  • One aim of the present study was to compare levels of immunohistochemical (IHC) expression of p53 tumour suppressor gene and bcl-2 oncoprotein between UPSC and IEN, as well as normal endometrium to determine its biologic significance.
  • MATERIALS AND METHODS: An immunoreactivity score was assigned for examination of p53 and bcl-2 expression in a total of 21 cases of UPSC, 9 with an evaluable IEN component and 11 with associated non-neoplastic endometrium.
  • RESULTS: p53 was identified in 16/21 cases of UPSC (76%) and 8/9 cases of IEN (89%), and no cases of normal endometrium.
  • Differences in immunoreactive scores for both p53 and bcl-2 between UPSC and benign glands, as well as between IEN and benign glands reached statistical significance with P values of 0.006 and 0.014 for p53, and 0.003 and 0.027 for bcl-2 respectively.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Endometrium / pathology. Gene Expression Regulation, Neoplastic. Neoplasm Invasiveness / pathology. Precancerous Conditions / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Atrophy / pathology. Biomarkers, Tumor / analysis. Biopsy, Needle. Case-Control Studies. Female. Genes, p53 / genetics. Humans. Immunohistochemistry. Probability. Prognosis. Proto-Oncogene Proteins c-bcl-2 / genetics. Reference Values. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123814.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


8. Giordano G, D'Adda T, Gnetti L, Merisio C, Raboni S: Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature. Int J Gynecol Pathol; 2007 Jul;26(3):298-304
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature.
  • Transitional cell carcinoma of the endometrium (TCCE) is a subtype of endometrial carcinoma, characterized by a prominent papillary pattern, resembling the papillary carcinoma of the urothelium.
  • This neoplasm is very rare, with only 13 cases reported in the international literature.
  • In this paper, a new case of TCCE associated with benign ovarian Brenner tumor is described.
  • Moreover, immunohistochemical and molecular studies are carried out in the effort to establish the phenotype and etiology of this rare neoplasm.
  • The molecular study, by polymerase chain reaction (PCR) failing to reveal the presence of HPV DNA, demonstrates that neither the TCCE nor the ovarian Brenner tumor is caused by an HPV infection.
  • The association of TCCE with benign ovarian Brenner tumor could be a coincidental event.
  • In our view, other cases of TCCE associated with ovarian Brenner tumor should be reported to confirm the last 2 hypotheses.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Transitional Cell / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581415.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


9. Balasenthil S, Broaddus RR, Kumar R: Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol; 2006 Jun;37(6):656-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas.
  • Endometrial carcinoma is one of the most common malignancies of the female genital tract.
  • MTA1 expression has been demonstrated in various cancers but has never been explored in endometrial carcinoma.
  • We investigated the expression profile of MTA1 in different stages of benign endometrium as well as in endometrial endometrioid adenocarcinoma using immunohistochemistry and Western blotting.
  • Western blot analysis of 6 tumor specimens showed increased expression of MTA1 in all the tumors analyzed.
  • Immunohistochemical staining performed on tumor microarray containing 70 endometrial endometrioid adenocarcinomas of various grades showed increased expression of MTA1 in 53 (75.7%) tumors.
  • Our results suggest a potential role of MTA1 in endometrial carcinomas.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Endometrium / metabolism. Gene Expression. Histone Deacetylases / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733204.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 098823
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


10. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • To investigate the potential use of MGB in gynecologic pathology practice, we tested MGB expression by immunohistochemistry on 47 endocervical adenocarcinomas (whole tissue sections of 13 invasive and 35 in situ) and 55 endometrial carcinomas (39 endometrioid and 16 nonendometrioid represented on a single tissue microarray).
  • Nonneoplastic endocervical and endometrial tissues were also evaluated for MGB expression.
  • MGB expression was detected in thirty (77%) of 39 of endometrioid endometrial adenocarcinomas compared with 4 (31%) of 13 endocervical adenocarcinomas.
  • MGB was mostly negative in nonendometrioid endometrial carcinoma (negative in 14 [88%] of 16).
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • These results confirm that MGB is not specific for breast carcinoma, but is also variably expressed in nonneoplastic and neoplastic endocervical and endometrial tissues.
  • Frequent MGB expression in endometrioid endometrial adenocarcinoma is significantly different from nonendometrioid carcinoma.
  • Hormone receptor status is not associated with MGB expression in endometrial carcinomas.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


11. Gashaw I, Stiller S, Böing C, Kimmig R, Winterhager E: Premenstrual regulation of the pro-angiogenic factor CYR61 in human endometrium. Endocrinology; 2008 May;149(5):2261-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premenstrual regulation of the pro-angiogenic factor CYR61 in human endometrium.
  • In this study we investigated the temporal and spatial expression pattern in human endometrium during the menstrual cycle and its possible regulation mechanisms in the premenstrual phase.
  • Because the menstrual breakdown of the functionalis is triggered by cytokines, prostaglandins (PGs), as well as hypoxia, we used a benign endometrial cell line to investigate if CYR61 is regulated by these factors.
  • The opposite effect of TNFalpha combined with hypoxia on CYR61 up-regulation could contribute to a balanced expression level of this angiogenic factor in the endometrium.
  • [MeSH-major] Endometrium / metabolism. Gene Expression Regulation. Immediate-Early Proteins / genetics. Intercellular Signaling Peptides and Proteins / genetics. Menstrual Cycle / physiology. Neovascularization, Physiologic / genetics
  • [MeSH-minor] Adolescent. Adult. Angiogenesis Inducing Agents / metabolism. Cell Hypoxia / genetics. Cell Hypoxia / physiology. Cells, Cultured. Cohort Studies. Cysteine-Rich Protein 61. Cytokines / physiology. Dinoprostone / physiology. Female. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / physiology. Middle Aged. RNA, Messenger / metabolism. Tumor Necrosis Factor-alpha / metabolism. Tumor Necrosis Factor-alpha / physiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202125.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / CYR61 protein, human; 0 / Cysteine-Rich Protein 61; 0 / Cytokines; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


12. Junaid I, Paz R, Salihu HM, Sharma PP, Aliyu ZY: Pseudo-Meig's syndrome with multiple synchronous benign and malignant pelvic tumors. Arch Gynecol Obstet; 2006 Feb;273(5):315-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-Meig's syndrome with multiple synchronous benign and malignant pelvic tumors.
  • BACKGROUND: Meig's and Pseudo-Meig's syndromes have been reported in association with several malignancies but the concomitant existence of multiple synchronous benign and malignant tumors in association with Pseudo-Meigs' syndrome has not been reported in the published literature.
  • Histological examination confirmed a right ovarian carcinoid tumor embedded within a mature cystic teratoma while the left ovary, fallopian tube and the uterus contained a poorly differentiated adenocarcinoma of the endometrium.
  • CONCLUSION: This is the first case report of Pseudo-Meig's syndrome in association with ovarian carcinoid tumor and multiple synchronous benign and malignant pelvic tumors.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Asthma / complications. CA-125 Antigen / blood. Carcinoid Tumor / complications. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Endometrial Neoplasms / complications. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / complications. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Hydrothorax / complications. Middle Aged. Ovarian Neoplasms / complications. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Teratoma / complications. Teratoma / pathology. Teratoma / surgery. Uterine Neoplasms / complications. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136360.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


13. Brys M, Semczuk A, Rechberger T, Krajewska WM: Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. Oncol Rep; 2007 Jul;18(1):261-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium.
  • Overexpression of the erbB-1 (EGFR, epidermal growth factor receptor) and erbB-2 (HER2/neu) proteins contributes to the aggressive behavior of malignant tumors originating from the endometrium.
  • The level of expression appeared to be significantly higher in the malignant tumors as compared to the benign ones for erbB-1 and for erbB-2 (p=0.0001 and p=0.008, respectively).
  • A significant correlation between erbB-1 overexpression and tumor differentiation was found (Spearman rank correlation test, p<0.001).
  • Our data suggest that erbB-1/erbB-2 overexpression is a direct effect of higher than normal transcriptional activity of the encoding genes in a subset of human endometrial carcinomas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Carcinoma, Adenosquamous / genetics. Endometrial Neoplasms / genetics. Endometrium / metabolism. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549377.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


14. Liu Y: Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls. Ann Nucl Med; 2009 Feb;23(2):107-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls.
  • Increased ovarian or endometrial uptake may cause a dilemma in the interpretation of whole body F18-fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging or even misdiagnosis of malignant disease.
  • Knowledge of benign FDG uptake of the ovaries and uterus is important for daily practice of nuclear medicine radiologists.
  • In premenopausal women, increased ovarian or endometrial uptake can be functional or malignant.
  • Benign functional uptake of premenopausal ovaries or uterus is related to the menstrual cycle; therefore, information about the patient's menstrual status is crucial for interpretation.
  • Increased ovarian uptake may also be identified in histologically different benign tumor entities.
  • Nonmenstrual-related endometrial uptake may be present in many benign diseases as well.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Fluorodeoxyglucose F18 / pharmacokinetics. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / metabolism. Ovary / metabolism. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Artifacts. Diagnosis, Differential. Female. Humans. Radiopharmaceuticals / pharmacokinetics

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225932.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 41
  •  go-up   go-down


15. Xiong Y, Xiong YY, Zhou YF: Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma. Eur J Gynaecol Oncol; 2010;31(2):160-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma.
  • OBJECTIVE: The aim of this study was to explore the potentiality of beta-catenin, Glut-1 and PTEN proteins as markers for a diagnosis of endometrial intraepithelial neoplasia (EIN).
  • DESIGN: Ten proliferative endometrium, 83 endometrial hyperplasia (59 benign hyperplasia, 24 EIN) and 24 endometrioid adenocarcinoma sections were immunostained for beta-catenin, Glut-1 and PTEN protein expression. RESULTS:.
  • (1) Abnormal expression of beta-catenin was detected in 10% of benign hyperplasia, 50% of EIN and 67% of endometriold adenocarcinoma. (2) Overexpression of Glut-1 was present in 58% of EIN and 71% of endometrioid adenocarcinoma. (3) Complete loss of PTEN immunoreactivity was found in 20% of proliferative endometrium, 29% of benign hyperplasia, 38% of EIN and 63% of endometrioid adenocarcinoma.
  • CONCLUSIONS: The abnormal expression of beta-catenin and overexpression of Glut-1 may be useful markers in distinguishing benign hyperplasia from EIN, whereas lack of PTEN expression is not an appropriate marker for a diagnosis of EIN.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Glucose Transporter Type 1 / metabolism. PTEN Phosphohydrolase / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20527231.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / beta Catenin; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


16. Trahan S, Têtu B, Raymond PE: Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases. Hum Pathol; 2005 Dec;36(12):1316-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases.
  • Serous papillary carcinoma is an aggressive tumor.
  • Point mutations in the p53 suppressor gene might explain in part the rapid growth of this malignant tumor and its unfavorable outcome.
  • The aims of this study were to evaluate the behavior of serous papillary carcinoma developing in endometrial polyps and to assess the p53 protein overexpression.
  • Thirteen serous papillary carcinomas arising from benign polyps of the endometrium were identified.
  • A serous papillary carcinoma arising from benign polyps of the endometrium remains a malignant neoplasia with an unfavorable outcome even if the primary tumor is limited to the polyp.
  • The high rate of protein p53 overexpression suggests that a p53 gene mutation occurs early in the disease and might explain the rapid growth of the tumor.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Polyps / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease-Free Survival. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311126.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


17. Afify AM, Craig S, Paulino AF, Stern R: Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol; 2005 Dec;9(6):312-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium.
  • The interaction between epithelial tumor cells and their surrounding stroma is important in tumor progression and metastasis.
  • The purpose of this study was to evaluate the significance of HA, CD44s, and CD44v6 in benign, hyperplastic, atypical, and malignant endometrial epithelia.
  • Archival paraffin-embedded cell blocks from proliferative endometrium (n = 11), secretory endometrium (n = 12), simple hyperplasia (n = 13), complex hyperplasia without atypia (n = 9), complex hyperplasia with atypia (n = 17), and adenocarcinoma (n = 21) were stained for HA, CD44s, and CD44v6.
  • The endometrial stromal cells expressed CD44v6 in 1 (8%) case of simple hyperplasia, 6 (67%) of complex hyperplasia without atypia, 8 (47%) of complex hyperplasia with atypia, and in 3 (14%) of adenocarcinoma.
  • We concluded that in the normal menstrual cycle, the timing of peak staining of HA and CD44s in the stroma and the up-regulation of CD44v6 in secretory glands are coincident with the period in which the endometrium is most receptive to embryo implantation.
  • HA is more abundant in the stroma adjacent to the tumor, suggesting that interactions between tumor cells and stromal HA promote tumorigenesis.
  • Thus, HA and CD44 are both involved in the development and progression of endometrial cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD44 / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Glycoproteins / metabolism. Hyaluronic Acid / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308159.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44v6 antigen; 0 / Glycoproteins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


18. Konishi Y, Sato H, Fujimoto T, Tanaka H, Takahashi O, Tanaka T: Adenofibroma of the endometrium protruding into the vaginal cavity: findings on transvaginal ultrasonography, MRI and CT. J Obstet Gynaecol Res; 2006 Dec;32(6):623-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma of the endometrium protruding into the vaginal cavity: findings on transvaginal ultrasonography, MRI and CT.
  • Adenofibroma is a rare benign biphasic neoplasm that is classified into the mixed epithelial and mesenchymal tumor group.
  • We report the case of a 42-year-old woman with adenofibroma of the endometrium protruding into the vagina.
  • Transvaginal ultrasonography revealed the tumor as an intravaginal mass containing multiple cystic components.
  • Although preoperative diagnosis of this rare tumor is very difficult, the combination of MRI, CT, and ultrasonography offers a useful diagnostic tool.
  • [MeSH-major] Adenofibroma / ultrasonography. Endometrial Neoplasms / ultrasonography. Vagina / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100829.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Hwang JH, Lee JK, Lee NW, Lee KW: Primary small cell carcinoma of the endometrium: report of a case with immunochemical studies. J Reprod Med; 2010 Jan-Feb;55(1-2):81-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of the endometrium: report of a case with immunochemical studies.
  • BACKGROUND: Small cell carcinoma (SCC) is a well-known tumor that occurs predominantly in the lung.
  • Primary SCC of the endometrium is extremely rare.
  • We report a case of an endometrial tumor that was a combination of an SCC and endometrioid adenocarcinoma with squamous components and that penetrated half of the thickness of the uterine wall.
  • CONCLUSION: Immunohistochemical analyses are helpful in diagnosing and differentiating primary SCC of the endometrium from benign and malignant diseases of the endometrium.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337215.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Synaptophysin
  •  go-up   go-down


20. Fujii S, Matsusue E, Kigawa J, Sato S, Kanasaki Y, Nakanishi J, Sugihara S, Kaminou T, Terakawa N, Ogawa T: Diagnostic accuracy of the apparent diffusion coefficient in differentiating benign from malignant uterine endometrial cavity lesions: initial results. Eur Radiol; 2008 Feb;18(2):384-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of the apparent diffusion coefficient in differentiating benign from malignant uterine endometrial cavity lesions: initial results.
  • Our purpose is to evaluate the diagnostic accuracy of apparent diffusion coefficient (ADC) measurement in differentiating malignant from benign uterine endometrial cavity lesions.
  • We retrospectively evaluated 25 uterine endometrial cavity lesions in 25 female patients: endometrial carcinoma (n = 11), carcinosarcoma (n = 2), submucosal leiomyoma (n = 8), and endometrial polyp (n = 4).
  • The region of interest was defined within the tumor on T2-weighted EPI image and then manually copied to an ADC map.
  • We compared ADC values between malignant and benign lesions using Student's t-test.
  • The mean and standard deviation of ADC values (x10(-3) mm(2)/s) were as follows: endometrial carcinoma, 0.98+/-0.21; carcinosarcoma, 0.97+/-0.02; submucosal leiomyoma, 1.37+/-0.28; and endometrial polyp, 1.58+/-0.45.
  • The ADC values differed significantly between malignant (0.98+/-0.19) and benign lesions (1.44+/-0.34) (P < 0.01).
  • ADC measurement can provide useful information in differentiating malignant from benign uterine endometrial cavity lesions.
  • [MeSH-major] Carcinosarcoma / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Endometrial Neoplasms / diagnosis. Endometrium / pathology. Leiomyoma / diagnosis. Polyps / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Middle Aged. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2004 Oct;77(922):851-7 [15482997.001]
  • [Cites] Radiology. 2000 Jan;214(1):47-52 [10644100.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):319-24 [16786565.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S131-45 [10517450.001]
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):53-60 [10030650.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jul;187(1):181-4 [16794174.001]
  • [Cites] J Magn Reson Imaging. 2005 Aug;22(2):271-8 [16028258.001]
  • [Cites] Radiology. 2005 Jun;235(3):911-7 [15845792.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):275-82 [15468951.001]
  • [Cites] Eur Radiol. 2007 Jan;17(1):201-4 [16865369.001]
  • [Cites] J Magn Reson Imaging. 2005 Mar;21(3):258-62 [15723379.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1362-9 [16775298.001]
  • [Cites] AJR Am J Roentgenol. 2001 Aug;177(2):449-54 [11461881.001]
  • [Cites] Magn Reson Imaging. 2002 Jul;20(6):463-70 [12361793.001]
  • [Cites] Magn Reson Med Sci. 2005;4(1):35-42 [16127252.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):83-6 [15665689.001]
  • [Cites] NMR Biomed. 1995 Nov-Dec;8(7-8):289-96 [8739267.001]
  • [Cites] Radiology. 2005 Jul;236(1):196-203 [15987974.001]
  • [Cites] Eur Radiol. 2007 Jun;17(6):1385-93 [17206421.001]
  • [Cites] J Magn Reson Imaging. 2004 Jul;20(1):97-104 [15221814.001]
  • [Cites] Eur Radiol. 2005 Jan;15(1):71-8 [15538578.001]
  • [Cites] Eur Radiol. 2006 Jul;16(7):1591-8 [16496154.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1419-25 [16908550.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):1014-9 [11105044.001]
  • [Cites] Eur Radiol. 2002 Nov;12(11):2737-42 [12386766.001]
  • [Cites] Eur Radiol. 2005 Nov;15(11):2244-55 [16228215.001]
  • [Cites] J Magn Reson Imaging. 2007 Sep;26(3):682-7 [17729360.001]
  • [Cites] J Comput Assist Tomogr. 2002 Mar-Apr;26(2):250-6 [11884782.001]
  • [Cites] Radiology. 2002 Jul;224(1):177-83 [12091680.001]
  • [Cites] Magn Reson Imaging. 1999 Dec;17(10):1445-55 [10609993.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • (PMID = 17917730.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Czekierdowski A, Czekierdowska S, Czuba B, Cnota W, Sodowski K, Kotarski J, Zwirska-Korczala K: Microvessel density assessment in benign and malignant endometrial changes. J Physiol Pharmacol; 2008 Sep;59 Suppl 4:45-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvessel density assessment in benign and malignant endometrial changes.
  • Tumor angiogenesis is believed to be a prognostic indicator associated with tumor growth and metastasis.
  • Microvessel density (MVD) assessment with common endothelial markers such as CD34 has been found to influence prognosis among endometrial carcinoma patients.
  • The aim of this study was to evaluate the quantification of angiogenesis by assessing MVD in endometrial lesions when comparing the performance of anti-CD34 and anti-CD105 in women with benign and malignant endometrial changes.
  • The study included 58 women (37 postmenopausal) with normal, hyperplastic and malignant endometrium in which preoperative transvaginal sonography was performed.
  • Histological results of the removed endometrium were correlated with MVD assessed in "hot areas" where high densities of microvessels were detected within tumoral tissue.
  • Endometrial cancer was confirmed in 37 women (3 premenopausal).
  • Benign hyperplasia (14 cases), secretory or proliferative endometrium (5 cases) or endometrial atrophy (2 cases) was found in the remaining women.
  • Median MVD assessed with CD34 was almost twice higher in women with endometrial cancer than in women with benign endometrium (CD34 MVD = 41.8 vs. 27.6, p=0.004).
  • In cases of CD105 MVD significant differences between women with benign and malignant endometrial changes were also found (CD105 MVD = 11.8, vs. 6.4; p=0.00007).
  • In conclusion, transition from endometrial hyperplasia to endometrial cancer appears to be accompanied by microvessel density changes.
  • MVD assessed with both CD34 and CD105 antibodies could be used as a potential prognostic factor in women with endometrial cancer.
  • Our study showed that endoglin, by staining the proliferating microvessels could be more specific and sensitive marker for tumor neoangiogenesis than the more commonly used marker, CD34.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Neoplasms / blood supply. Microvessels. Neovascularization, Pathologic / ultrasonography
  • [MeSH-minor] Antigens, CD / analysis. Antigens, CD / biosynthesis. Antigens, CD34 / analysis. Antigens, CD34 / biosynthesis. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Cell Surface / analysis. Receptors, Cell Surface / biosynthesis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955753.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


22. Koviazin VA, Shchelokova EE, Kostanian IA, Dranitsyna SM, Frolova II, Babichenko II: [The proapoptotic factor HLDF in the normal, hyperplastic and neoplastic endometrium]. Arkh Patol; 2007 May-Jun;69(3):23-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The proapoptotic factor HLDF in the normal, hyperplastic and neoplastic endometrium].
  • Antibodies to the factor HLDF are shown to be specific markers of apoptosis and permit the estimation of the rate of programmed cell death in the course of a normal menstrual cycle and in pathologic endometrial processes.
  • Antibodies to the HLDF factor may be used as a new immunohistochemical marker for the differential diagnosis of benign and malignant endometrial processes.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Hyperplasia / diagnosis. Endometrial Neoplasms / diagnosis. Neoplasm Proteins / analysis
  • [MeSH-minor] Antibodies / immunology. Apoptosis. Endometrium / pathology. Female. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722590.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / cell differentiation factor 8.2-kDa
  •  go-up   go-down


23. Visnovský J, Galo S, Zúbor P, Hatok J, Racay P, Danko J: [Semiquantitative analysis of mRNA aromatase expression in eutopic endometrium as a diagnostic marker of endometriosis and estrogen dependent diseases]. Ceska Gynekol; 2008 Jul;73(4):213-7
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Semiquantitative analysis of mRNA aromatase expression in eutopic endometrium as a diagnostic marker of endometriosis and estrogen dependent diseases].
  • OBJECTIVE: To determine clinical benefits of mRNA aromatase expression in entopic endometrium as a diagnostic marker of endometriosis.
  • METHODS: The expression of mRNA aromatase of eutopic endometrium was determined among women who underwent laparoscopy or laparotomy due to pelvic pain, infertility or benign pelvic tumor.
  • By the presence of estrogen-dependent diseases- endometriosis, myomas or endometrial hyperplasia 18 women were compared to 5 disease free women.
  • CONCLUSION: Aromatase expression in eutopic endometrium is a good diagnostic marker for endometriosis.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711959.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] SLO
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Estrogens; 0 / RNA, Messenger; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


24. Norimatsu Y, Miyamoto T, Kobayashi TK, Oda T, Moriya T, Yanoh K, Miyake Y, Ohno E: Utility of thin-layer preparations in endometrial cytology: immunocytochemical expression of PTEN, beta-catenin and p53 for benign endometrial lesions. Diagn Cytopathol; 2008 Apr;36(4):216-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of thin-layer preparations in endometrial cytology: immunocytochemical expression of PTEN, beta-catenin and p53 for benign endometrial lesions.
  • This article focuses on the characteristic features of morphology and molecular biology of PTEN, beta-catenin, and p53 immunocytochemistry in normal endometrium (proliferative, secretory, and atrophic) and endometrial glandular and stromal breakdown (EGBD) using thin-layer specimens.
  • During a 6-month period, 120 endometrial samples were collected directly using the Uterobrush and a thin-layer specimen was prepared.
  • Immunocytochemical expression of PTEN, beta-catenin, and p53 were investigated using 30 cases each of proliferative endometrium (PE), secretory endometrium (SE), atrophic endometrium (AE), and EGBD.PTEN expression of normal endometrial glandular epithelial cells changes with the hormonal status; PE produce very high expression, SE creates attenuation or disappearance of PTEN expression and AE diminished more in comparison with SE.
  • In the current study, the expression manner of PTEN, beta-catenin, and p53 immunocytochemistry was observed in the normal endometrium (PE, SE, and AE) and EGBD.
  • [MeSH-major] Endometrium / cytology. Epithelial Cells / cytology. Epithelial Cells / metabolism. PTEN Phosphohydrolase / metabolism. Tumor Suppressor Protein p53 / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Antibodies, Neoplasm / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18335551.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


25. Farrell R, Scurry J, Otton G, Hacker NF: Clinicopathologic review of malignant polyps in stage 1A carcinoma of the endometrium. Gynecol Oncol; 2005 Aug;98(2):254-62
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic review of malignant polyps in stage 1A carcinoma of the endometrium.
  • OBJECTIVES: The aims of this study were to determine the incidence of malignant polyps in stage 1A endometrial cancer, to define the pathological features of such cancers, and to assess whether clinical outcome differs from similar cancers without a malignant polyp.
  • METHODS: We performed a retrospective pathological review of 107 cases of stage 1A endometrial cancer treated at two centers in New South Wales between January 1988 and July 2003.
  • The presence of a malignant polyp was determined and a pathological description made of the tumor.
  • Clinical data were collected, including prior tamoxifen usage, tumor recurrence and survival.
  • Precursor lesions of endometrial cancer were identified within malignant polyps.
  • Three out of the four recurrences occurred in high-grade tumor subtypes and all four had a large primary tumor (size > or = 4 cm).
  • When comparing the same subtype of tumor with and without a malignant polyp, there was no significant difference in clinical outcome.
  • CONCLUSIONS: Approximately one-third of stage 1A endometrial cancers are associated with a malignant polyp.
  • Serous carcinoma commonly arises within an otherwise benign endometrial polyp.
  • Malignant polyps offer an opportunity to identify precursors of endometrial carcinoma.
  • Clinical outcome of stage 1A endometrial carcinoma was related to the histological subtype and the size of the tumor rather than the presence of a malignant polyp.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Polyps / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Tamoxifen / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936803.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


26. Coosemans A, Moerman P, Verbist G, Maes W, Neven P, Vergote I, Van Gool SW, Amant F: Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol; 2008 Dec;111(3):502-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
  • OBJECTIVE: Wilms' tumor gene (WT1), located on chromosome 11, encodes a transcription factor that contributes to the carcinogenesis of uterine sarcomas.
  • To expand the knowledge on the biological role of WT1 in other uterine cancers, we focused on its detection in endometrial carcinoma.
  • METHODS: In total, 36 paraffin-embedded tumors were available for WT1 immunohistochemical (IHC) analysis including endometrial endometrioid carcinoma (n=24), serous carcinoma (n=9) and clear cell carcinoma (n=3).
  • Three slides from different sites of the tumor were analysed.
  • To compare, WT1 expression was also evaluated by IHC in benign endometrium (12) and benign endometrial polyps (5).
  • RESULTS: WT1 positivity was noticed in tumor cells and endothelial cells, lining the intratumoral blood vessels.
  • Comparing the staining patterns of the 3 different bioptic sites, tumor heterogeneity was demonstrated in the majority (72%) of samples.
  • CONCLUSION: Although WT1 is expressed in a majority of endometrial carcinomas, a heterogeneous staining pattern is observed.
  • [MeSH-major] Endometrial Neoplasms / genetics. Genes, Wilms Tumor
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Aged. Biopsy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction. WT1 Proteins / biosynthesis. WT1 Proteins / genetics

  • Genetic Alliance. consumer health - Wilms' tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929401.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


27. Mangioni S, Viganò P, Florio P, Borghi O, Vignali M, Petraglia F, Di Blasio AM: Effect of activin A on tumor necrosis factor-alpha/intercellular adhesion molecule-1 pathway in endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol; 2005 Dec 1;123(2):218-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of activin A on tumor necrosis factor-alpha/intercellular adhesion molecule-1 pathway in endometrial stromal cells.
  • OBJECTIVE[S]: Activin A and inhibin A are growth factors expressed by human endometrium involved in the control of endometrial functions.
  • In the present study we investigated the effects of activin A and inhibin A in modulating the tumor necrosis factor (TNF)-alpha/intercellular adhesion molecule (ICAM)-1 system in cultured human endometrial stromal cells.
  • STUDY DESIGN: Endometrial samples were obtained from 34 reproductive age women undergoing laparoscopy for benign ovarian cysts or infertility.
  • Endometrial stromal cells were cultured and soluble ICAM-1 and TNF-alpha were measured in cell-free supernatants following treatment with or without activin A or inhibin A.
  • Cell surface ICAM-1 was assayed by flow cytometry by staining endometrial cells with specific monoclonal antibodies.
  • RESULTS: Activin A and inhibin A did not influence either the expression of cell surface ICAM-1 or soluble ICAM-1 shedding by cultured endometrial cells.
  • CONCLUSIONS: Since TNF-alpha modulates several endometrial processes such as menstruation, proliferation, apoptosis, implantation and decidualization, an effect of activin A in the physiological control of endometrium is further supported by the present data.
  • [MeSH-major] Activins / pharmacology. Endometrium / drug effects. Immunologic Factors / pharmacology. Inhibin-beta Subunits / pharmacology. Intercellular Adhesion Molecule-1 / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893868.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interleukin-1; 0 / Tumor Necrosis Factor-alpha; 0 / activin A; 0 / inhibin A; 104625-48-1 / Activins; 126547-89-5 / Intercellular Adhesion Molecule-1; 57285-09-3 / Inhibins; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


28. Barroeta JE, Pasha TL, Acs G, Zhang PJ: Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement. Int J Gynecol Pathol; 2007 Jan;26(1):76-82
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement.
  • To evaluate and compare the immunophenotype of endocervical and endometrial stromal cells and to asses its potential application in tumor localization.
  • Paraffin sections of benign endocervix (n = 24), benign endometrium (n = 33), endocervical adenocarcinoma (n = 9), endometrial carcinoma (n = 13), and endometrial hyperplasia (n = 16) were stained with antibodies to CD10, Wilms Tumor-1, CD34, smooth muscle actin, and factor XIIIa by immunohistochemistry.
  • Endocervical stromal cells (ECSC) in either benign or malignant cervical epithelial lesions were predominantly CD34/CD10 (CD34 dominant immunophenotype).
  • Endometrial stromal cells (EMSCs) in either benign or malignant epithelial lesions were primarily CD34/CD10 (CD10 dominant immunophenotype).
  • Expression of Wilms Tumor-1 was decreased in EMSC of the EMCA when compared to their counterpart in endometrial hyperplasia.
  • The functional status of the endometrium had no effect on the immunoprofile.
  • The pattern of CD34 and CD10 immunostaining in stromal cells might be helpful in determining tumor involvement in uterine and cervical sites.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Stromal Cells / metabolism. Stromal Cells / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197901.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Pino M, Galleguillos C, Torres M, Sovino H, Fuentes A, Boric MA, Johnson MC: Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis. Reproduction; 2009 Nov;138(5):837-47
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis.
  • Endometriosis is a benign gynecological pathology in which immune system deregulation may play a role in its initiation and progression.
  • The objective of our study was to investigate the association between MMP1 and MMP9 activities and ICAM1 cleavage mediated by tumor necrosis factor (TNF) in eutopic endometrial stromal cells from women with and without (control) endometriosis during culture.
  • [MeSH-major] Endometriosis / pathology. Endometrium / pathology. Intercellular Adhesion Molecule-1 / metabolism. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Stromal Cells / drug effects. Tumor Necrosis Factor-alpha / pharmacology. Uterine Diseases / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661147.001).
  • [ISSN] 1741-7899
  • [Journal-full-title] Reproduction (Cambridge, England)
  • [ISO-abbreviation] Reproduction
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


30. Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA: Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. Am J Surg Pathol; 2005 Oct;29(10):1348-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors.
  • Inflammatory myofibroblastic tumor (IMT) is an indolent spindle cell proliferation that can histologically resemble various malignant mesenchymal neoplasms; however, it generally behaves as a benign or locally recurrent tumor.
  • The three other tumors grew as bulky myometrial masses with focally irregular borders and infiltrated the endometrium, parametrium, or cervical stroma.
  • Mitotic activity ranged from 0 to 2 mitotic figures per 10 high power fields (HPF) except in one tumor that focally had up to 8 mitotic figures per 10 HPF.
  • No ALK expression was identified in uterine leiomyoma (n = 7), leiomyosarcoma (n = 6), carcinosarcoma (n = 4), endometrial stromal sarcoma (n = 4), or normal uterine tissues.
  • [MeSH-minor] Adolescent. Adult. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Sarcoma / metabolism. Sarcoma / pathology

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160478.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


31. Jia L, Liu Y, Yi X, Miron A, Crum CP, Kong B, Zheng W: Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res; 2008 Apr 15;14(8):2263-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.
  • PURPOSE: Endometrial glandular dysplasia (EmGD) has been recently proposed to be a putative precursor to endometrial serous carcinoma (ESC).
  • EXPERIMENTAL DESIGN: The tumor suppressor p53 gene was sequenced from serial samples of benign and neoplastic endometria with serous differentiation.
  • The study group contained 15 neoplastic uteri and the control group had 12 age-matched benign uteri.
  • A total of 139 informative samples were obtained, including 55 resting endometrium, 37 EmGD, 25 serous endometrial intraepithelial carcinoma (EIC), and 22 ESC.
  • RESULTS: The mutations of p53 were detected in 0%, 43%, 72%, and 96% in resting endometrium, EmGD, serous EIC, and ESC, respectively.
  • Mutation of p53 gene is probably one of the most important factors to initiate the endometrial serous carcinogenesis.
  • Correct identification of EmGD will provide us an opportunity of early diagnosis and a potentially effective therapeutic modality to control ESC.
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. Endometrial Neoplasms / genetics. Endometrium / pathology. Genes, p53. Mutation. Precancerous Conditions / genetics
  • [MeSH-minor] Aged. Base Sequence. Female. Humans. Middle Aged. Molecular Sequence Data. Tumor Suppressor Protein p53 / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18369088.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA23074
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


32. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z: The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol; 2008 Feb;32(2):304-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
  • Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein highly expressed in fetal tissue and malignant tumors but rarely found in adult benign tissues.
  • The aim of this study is to determine the expression of IMP3 in benign endometrium, endometrial cancer, and its precursor lesions, trying to see whether IMP3 has any diagnostic usage.
  • Two hundred ninety-eight endometrial samples were examined for IMP3 expression by immunohistochemistry.
  • These included benign endometrium (n=68), atypical hyperplasia or endometrial intraepithelial neoplasia (n=35), endometrial glandular dysplasia (n=21), endometrial intraepithelial carcinoma (n=18), endometrioid carcinoma (n=70), mucinous carcinoma (n=8), serous carcinoma (n=51), clear cell carcinoma (n=12), and other malignancies (n=15).
  • Maturational patterns in the 68 benign endometrial samples included atrophic (n=12), proliferative (n=18), secretory (n=14), menstrual (n=8), and gestational (n=16).
  • Most of the carcinomas were histologically pure; where mixed, the second component constituted <10% of the total tumor volume.
  • Among the malignant cases, IMP3 expression was predominantly found in endometrial serous carcinoma and its putative precursor lesions, with 3 (14%) of 21 endometrial glandular dysplasia, 16 (89%) of 18 serous endometrial intraepithelial carcinoma, and 48 (94%) of 51 serous carcinomas (P<0.001).
  • In contrast, the frequency of IMP3 expression was significantly lesser in nonserous malignancies with 0 (0%) of 35, 5 (7%) of 70, 0 (0%) of 8, 3 (25%) of 12, and 5 (33%) of 15 positive expression rates in atypical hyperplasia or endometrial intraepithelial neoplasia, endometrioid, mucinous, clear cell carcinomas, and other malignancies, respectively.
  • Among the benign endometrial samples, decidualized endometrial stroma showed 100% positivity for IMP3.
  • We conclude that expression of IMP3, a newly identified cytoplasmic marker, is closely associated with type II endometrial cancer.
  • It seems that IMP3 expression is associated with an aggressive histologic phenotype among endometrial neoplastic lesions.
  • Strong and diffuse IMP3 expression is highly sensitive for endometrial serous and clear cell carcinomas including their putative precursor lesions.
  • Therefore, IMP3 may be a useful diagnostic marker in the assessment of endometrial cancers and their precursor lesions, particularly when the amount of available tissue material is limited and a concern of type II cancer arises.
  • High frequency of IMP3 expression is present in decidualized endometrial stroma of gestational endometrium and chorionic villi in early pregnancy.
  • Although the significance of the latter finding remains unclear, the differential diagnosis between decidual changes and endometrial serous carcinoma is rarely problematic.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / metabolism. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cytoplasm / metabolism. Cytoplasm / pathology. Endometrium / metabolism. Endometrium / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223334.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA23074
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


33. Hever A, Roth RB, Hevezi PA, Lee J, Willhite D, White EC, Marin EM, Herrera R, Acosta HM, Acosta AJ, Zlotnik A: Molecular characterization of human adenomyosis. Mol Hum Reprod; 2006 Dec;12(12):737-48
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomyosis is a common gynaecological disorder characterized by the abnormal growth of endometrium into the myometrium and myometrial hypertrophy/hyperplasia.
  • Uterine fibroids are benign neoplasms of the myometrium, and they represent a diagnostic pitfall for adenomyosis.
  • In this study, we have used the genome-wide Affymetrix U133 Plus 2.0 microarray platform to compare the gene expression patterns of adenomyosis, uterine fibroids, normal endometrium and myometrium.
  • Supervised cluster analysis based on these probe sets clustered adenomyosis most closely with endometrium and uterine fibroids with myometrium, consistent with the anatomic origin of these two diseases.
  • The Tukey means separation post hoc testing found 2073 probe sets altered between adenomyosis and normal endometrium or myometrium, and 2327 probe sets altered in expression when comparing uterine fibroids with myometrium.
  • Finally, we compared the gene expression profiles of adenomyosis and uterine fibroids and identified 471 differentially expressed probe sets that may represent potential biomarkers for the differential diagnosis of these diseases.
  • [MeSH-minor] Analysis of Variance. Biomarkers. Biomarkers, Tumor. Diagnosis, Differential. Endometrium / metabolism. Female. Humans. Leiomyoma / diagnosis. Leiomyoma / genetics. Leiomyoma / metabolism. Myometrium / metabolism. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Oligonucleotide Array Sequence Analysis. Principal Component Analysis. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Uterine Neoplasms / metabolism

  • Genetic Alliance. consumer health - Adenomyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020905.001).
  • [ISSN] 1360-9947
  • [Journal-full-title] Molecular human reproduction
  • [ISO-abbreviation] Mol. Hum. Reprod.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


34. Xie R, Loose DS, Shipley GL, Xie S, Bassett RL Jr, Broaddus RR: Hypomethylation-induced expression of S100A4 in endometrial carcinoma. Mod Pathol; 2007 Oct;20(10):1045-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypomethylation-induced expression of S100A4 in endometrial carcinoma.
  • We hypothesized that S100A4 would be overexpressed in endometrial carcinoma compared to benign endometrium.
  • Quantitative real-time RT-PCR (qRT-PCR) was used to quantify the mRNA level of S100A4 in benign endometrium (n=19), endometrioid adenocarcinoma (n=87), and non-endometrioid tumors (n=21).
  • S100A4 was overexpressed in the grade 3 endometrioid tumors, uterine papillary serous carcinoma, and uterine malignant mixed müllerian tumor.
  • Expression in grade 1 and grade 2 endometrioid tumors was comparable to that of normal endometrium, which was quite low.
  • By immunohistochemistry, S100A4 was expressed in the tumor cell cytoplasm of poorly differentiated tumors, but was not detected in normal endometrial glandular epithelium.
  • In benign endometrium, S100A4 expression was confined to stromal cells.
  • However, methylation of the S100A4 gene was detected in benign endometrium and grade 1 tumors with low S100A4 expression.
  • These methylation results were verified in endometrial cancer cell lines with differential baseline levels of S100A4 protein.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Endometrial Neoplasms / genetics. Gene Expression Regulation, Neoplastic. S100 Proteins / genetics
  • [MeSH-minor] Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Line, Tumor. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Endometrium / metabolism. Female. Gene Expression. Humans. Immunoenzyme Techniques. Mixed Tumor, Mullerian / genetics. Mixed Tumor, Mullerian / metabolism. Mixed Tumor, Mullerian / pathology. Neoplasm Staging. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673926.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CN / N01-CN-05127
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


35. Norimatsu Y, Moriya T, Kobayashi TK, Sakurai T, Shimizu K, Tsukayama C, Ohno E: Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women. Ann Diagn Pathol; 2007 Apr;11(2):103-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women.
  • Currently, the World Health Organization (WHO) classifies endometrial hyperplasia as a premalignant disease.
  • However, one of the problems in the current WHO endometrial hyperplasia schema is that it is not always a reproducible classification system.
  • Subsequently, the alternative molecular genetics and morphometric-based classification, referred to as the endometrial intraepithelial neoplasia (EIN) classification system, has been proposed.
  • We reclassified endometrial lesions in Japanese women using the EIN category and compared them with the results of PTEN as well as beta-catenin immunohistochemistry.
  • A total of 117 cases that were initially diagnosed as endometrial hyperplasia according to WHO classification were reevaluated histopathologically by the EIN diagnosis category.
  • They were classified into 38 EIN and 32 benign architectural changes of unopposed estrogen (BAC), and 47 cases were excluded.
  • In addition, for comparison, we examined 20 cases of normal proliferative endometrium (NPE).
  • Endometrial intraepithelial neoplasia was significantly less frequently positive for PTEN than NPE (P < .025).
  • [MeSH-major] Carcinoma in Situ / metabolism. Endometrial Neoplasms / metabolism. PTEN Phosphohydrolase / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Endometrium / metabolism. Female. Humans. Immunoenzyme Techniques. Japan. Middle Aged. Premenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349568.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


36. Fadare O, Liang SX, Ulukus EC, Chambers SK, Zheng W: Precursors of endometrial clear cell carcinoma. Am J Surg Pathol; 2006 Dec;30(12):1519-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursors of endometrial clear cell carcinoma.
  • The recognition of morphologically identifiable lesions which may confer an increased risk for subsequent development of an invasive malignancy offers an opportunity to investigate and better understand the molecular-genetic etiopathogenesis of the well-developed tumor, and potentially, to administer a therapeutic intervention before its development.
  • In contrast to uterine endometrioid and serous carcinomas, very little is known about the potential precursor lesions of endometrial clear cell carcinoma (ECCC).
  • In our routine practice, we have noted the presence of a spectrum of atypical glandular changes in the endometria adjacent to ECCC or endometrial carcinomas with a clear cell component, which on the basis of current criteria, would not qualify for any specific designation.
  • Thirty archived cases of pure ECCC (n=14) or mixed endometrial carcinomas with a >10% clear cell component (n=16) were retrieved and the "normal" endometria adjacent to the malignancies were evaluated in detail.
  • Thirty-eight benign uteri and 30 uteri with classic endometrial endometrioid carcinoma (EEC) served as controls.
  • The lesions were typically isolated glands or surface epithelium (within an otherwise normal endometrial region) that displayed cytoplasmic clarity and/or eosinophilia with varying degrees of nuclear atypia.
  • In contrast, PPL were identified neither in the benign uteri nor in endometrioid carcinoma control groups (P<0.001).
  • The immunohistochemical expression of p53, mib-1, estrogen receptor (ERs), and progesterone receptor in the benign endometria, ECCC, and the PPL were evaluated on all 27 cases.
  • The mean p53 scores for the benign endometria, PPL, and ECCC were 0, 4.5, and 6.2, respectively.
  • ER/progesterone receptor indices for benign endometria, PPL, and carcinoma were 90/80, 21.52/4.61, and 11/4, respectively.
  • The PPL described herein have a morphologic and immunophenotypic profile which seems to be distinct from both the benign endometria in which they reside and the adjacent areas of ECCC.
  • The high frequency of association of these lesions with ECCC, their frequent occurrence as isolated lesions within otherwise "benign-appearing" endometria, and their continuous spectrum of nuclear atypia from minimum (grade 1, cytologic atypia falls short of ECCC cells) to maximum (grade 3, cytologically identical to ECCC cells), argues in favor of our hypothesis that these may represent precursor lesions of ECCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Endometrium / chemistry. Endometrium / pathology. Exocrine Glands / chemistry. Exocrine Glands / pathology. Female. Humans. Immunoenzyme Techniques. Middle Aged. Single-Blind Method

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122507.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Houghton O, McCluggage WG: The expression and diagnostic utility of p63 in the female genital tract. Adv Anat Pathol; 2009 Sep;16(5):316-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is increased expression in cervical intraepithelial neoplasia, in accordance with the degree of dysplasia.
  • In the normal endometrium, a population of p63-positive cells is present which may act as a stem cell population and which is increased in various forms of metaplasia.
  • Placental site nodule and epithelioid trophoblastic tumor (lesions derived from chorionic-type intermediate trophoblast) are usually p63 positive whereas placental site reaction and placental site trophoblastic tumor (lesions derived from implantation site intermediate trophoblast) are usually negative; thus, p63 may be useful in the diagnostic algorithm of trophoblastic lesions. p63 positivity in ovarian epithelial tumors is uncommon and largely restricted to squamous and transitional neoplasms, including benign and borderline Brenner tumor. p63 is also positive in cervical transitional metaplasia, Walthard rests, vulval Paget disease secondary to an underlying urothelial malignancy, tubulosquamous polyp of the vagina, and ectopic prostatic tissue in the cervix.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Cervical Intraepithelial Neoplasia / diagnosis. Genital Neoplasms, Female / diagnosis. Hyperplasia / metabolism. Membrane Proteins / metabolism. Trophoblastic Tumor, Placental Site / metabolism
  • [MeSH-minor] Cell Nucleus / metabolism. Diagnosis, Differential. Female. Genitalia, Female / metabolism. Humans. Metaplasia / diagnosis. Metaplasia / metabolism. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700941.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  • [Number-of-references] 31
  •  go-up   go-down


38. Quddus MR, Ologun BA, Sung CJ, Steinhoff MM, Lawrence WD: Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia. Int J Gynecol Pathol; 2009 Sep;28(5):471-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia.
  • Surface epithelial changes (SECs) have been reported to be associated with endometrial carcinoma in about 49% of cases.
  • They have also been seen to be associated with endometrial hyperplasia.
  • Although morphologically benign, these lesions are considered a marker for underlying malignancy.
  • PTEN has been reported to be altered in endometrial carcinomas and endometrial precancers where no morphologic changes are appreciated.
  • The current study aims to investigate PTEN status in the endometrial SECs.
  • Thirty-two cases of endometrial biopsy are divided into 2 groups: group 1 had 18 cases of SEC and underlying endometrial atypical hyperplasia and group 2 had 14 cases of SEC alone.
  • Overall, PTEN alteration (NULL) was found in 12 of the 32 cases of endometrial samples (37.5%) examined.
  • In group 1, 10 of the 18 cases (56%) of atypical endometrial hyperplasia with "SECs" showed PTEN NULL.
  • Two other cases (20%) had atypical endometrial hyperplasia only.
  • These 2 patients were followed for 26 and 63 months, respectively, and subsequent endometrial biopsies and pap smears were negative.
  • Presence of PTEN NULL phenotype in SECs and associated endometrial hyperplasia does not necessarily predict an increased incidence of endometrioid carcinoma in subsequent follow-up.
  • However, absence of PTEN NULL phenotype in SECs alone may predict a benign follow-up.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Endometrium / pathology. PTEN Phosphohydrolase / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696618.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


39. Tanabe K, Matsumoto M, Ikematsu S, Nagase S, Hatakeyama A, Takano T, Niikura H, Ito K, Kadomatsu K, Hayashi S, Yaegashi N: Midkine and its clinical significance in endometrial carcinoma. Cancer Sci; 2008 Jun;99(6):1125-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Midkine and its clinical significance in endometrial carcinoma.
  • The purpose of this study was to determine whether MK was expressed in endometrial carcinoma and to evaluate the clinicopathological significance of serum MK in patients with endometrial carcinoma.
  • Immunohistochemical expression of MK was evaluated in 85 endometrial carcinoma samples and 33 controls.
  • MK expression was significantly higher in the carcinomas than in normal endometrium (P < 0.001).
  • Interestingly, MK expression was highest at the margins of invasion and low in the superficial areas of the tumor samples.
  • Using ELISA, we compared serum MK concentration in 120 endometrial carcinoma patients with the concentration in 46 patients with benign gynecologic tumors.
  • Serum MK value in patients with cancer was significantly higher than that in the patients with benign diseases (P = 0.01).
  • In conclusion, MK immunoreactivity in endometrial carcinoma is significantly higher than in normal endometrium.
  • Thus, MK may be a useful serum biomarker for identifying high risk patients of endometrial carcinoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Nerve Growth Factors / metabolism
  • [MeSH-minor] Enzyme-Linked Immunosorbent Assay. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422745.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MDK protein, human; 0 / Nerve Growth Factors
  •  go-up   go-down


40. Chen N, Yi X, Abushahin N, Pang S, Zhang D, Kong B, Zheng W: Nrf2 expression in endometrial serous carcinomas and its precancers. Int J Clin Exp Pathol; 2010 Dec 24;4(1):85-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nrf2 expression in endometrial serous carcinomas and its precancers.
  • Endometrial serous carcinoma (ESC) is the most aggressive subtype of endometrial cancer.
  • The aim of this study is to determine the Nrf2 expression in benign endometrium (n=28), endometrial cancers (n=122) as well as their precursor lesions (n=81) trying to see whether Nrf2 has any diagnostic usage and is potentially involved in endometrial carcinogenesis.
  • Among the malignant cases, Nrf2 was positive in 28 (68%) of 50 ESCs, which was significantly more than in 3 (6%) of 50 endometrioid carcinomas (p < 0.001) and 2 (13%) of 15 clear cell carcinomas (p = 0.001) and other histologic types of endometrial cancers.
  • Among endometrial precursor lesions, both serous endometrial glandular dysplasia (EmGD, 40%) and serous endometrial intraepithelial carcinoma (EIC, 44%) showed a significantly higher Nrf2 expression than that in atypical endometrial hyperplasia or endometrial intraepithelial neoplasia (0%), clear cell EmGD (10%), and clear cell EIC (25%), respectively.
  • We conclude that Nrf2 overexpression is closely associated with endometrial neoplasms with serous differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2005 Dec 11;591(1-2):93-102 [16054659.001]
  • [Cites] Mol Cell. 2009 Jun 26;34(6):663-73 [19560419.001]
  • [Cites] J Pathol. 2000 Mar;190(4):462-9 [10699996.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):797-806 [10843281.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):301-9 [11109157.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Feb;26(2):175-82 [11804867.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):326-31 [11986334.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Biochem J. 2004 Jun 1;380(Pt 2):515-21 [14960151.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7130-9 [15282312.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):207-23 [15306933.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] J Natl Cancer Inst. 1991 Mar 20;83(6):405-16 [1999848.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1463-73 [9850172.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):76-86 [9887101.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1248-59 [15520857.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10941-53 [15572695.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):579-82 [15721397.001]
  • [Cites] J Exp Med. 2005 Jul 4;202(1):47-59 [15998787.001]
  • [Cites] Mol Cell. 2006 Mar 3;21(5):689-700 [16507366.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • [Cites] PLoS Med. 2006 Oct;3(10):e420 [17020408.001]
  • [Cites] Drug Metab Rev. 2006;38(4):769-89 [17145701.001]
  • [Cites] Neurotoxicology. 2006 Dec;27(6):1094-100 [16959318.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):38-52 [17197896.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:89-116 [16968214.001]
  • [Cites] Free Radic Biol Med. 2007 Feb 15;42(4):433-45 [17275675.001]
  • [Cites] Pathology. 2007 Feb;39(1):46-54 [17365822.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 3;362(4):816-21 [17822677.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Eur J Pharmacol. 2009 Oct 12;620(1-3):138-44 [19698707.001]
  • [Cites] J Pathol. 2010 Mar;220(4):446-51 [19967722.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 Apr 1;244(1):37-42 [19538984.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 Apr 1;244(1):84-97 [19716833.001]
  • [Cites] Diabetes. 2010 Apr;59(4):850-60 [20103708.001]
  • [Cites] Cancer Res. 2010 Jul 1;70(13):5486-96 [20530669.001]
  • [Cites] Free Radic Biol Med. 2010 Dec 1;49(11):1603-16 [20840865.001]
  • [Cites] Curr Opin Obstet Gynecol. 2008 Feb;20(1):20-5 [18197001.001]
  • [Cites] Cancer Lett. 2008 Feb 18;260(1-2):96-108 [18036733.001]
  • [Cites] Am J Obstet Gynecol. 2008 Feb;198(2):218.e1-6 [18226630.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1235-43 [18413364.001]
  • [Cites] Free Radic Biol Med. 2008 Sep 1;45(5):651-8 [18572023.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7975-84 [18829555.001]
  • [Cites] Pharmacol Res. 2008 Nov-Dec;58(5-6):262-70 [18838122.001]
  • [Cites] Mol Carcinog. 2009 Feb;48(2):91-104 [18618599.001]
  • [Cites] Trends Biochem Sci. 2009 Apr;34(4):176-88 [19321346.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • (PMID = 21228930.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023074; United States / NIEHS NIH HHS / ES / R01 ES015010; United States / NCI NIH HHS / CA / P30 CA23074
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NF-E2-Related Factor 2; 0 / NFE2L2 protein, human
  • [Other-IDs] NLM/ PMC3016106
  • [Keywords] NOTNLM ; Nrf2 / endometrial cancer / endometrial glandular dysplasia / endometrial serous carcinoma / precancer
  •  go-up   go-down


41. Bershteĭn LM, Poroshina TE, Vasil'ev DA, Orlova AV: [Autoantibodies to steroid-producing ovarian cells in cancer patients]. Vopr Onkol; 2008;54(5):602-5
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our investigation included 158 women, aged 23-73: patients with tumors of the ovary, breast and endometrium--117 and subjects without oncological pathology--41.
  • Autoantibodies to microsomal fraction of follicular ovarian cells (> 500 Unit/ml) in healthy subjects were revealed 8.3% while in patients with ovarian, breast and endometrial malignancies (without significant differences between benign and malignant tumors) in 33.30%, 45.60% and 25.0%, respectively.
  • Higher level of anti-ovarian autoantibodies involved an inverse correlation between blood levels of FSH and estradiol in ovarian and endometrial carcinoma patients.
  • [MeSH-major] Autoantibodies / blood. Biomarkers, Tumor / blood. Breast Neoplasms / immunology. Endometrial Neoplasms / immunology. Gonadal Steroid Hormones / biosynthesis. Ovarian Neoplasms / immunology. Ovary / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069474.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Gonadal Steroid Hormones; 4TI98Z838E / Estradiol; 9002-68-0 / Follicle Stimulating Hormone; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


42. Kurman RJ, Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol; 2010 Mar;34(3):433-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, the carcinomas exhibit a shared lineage with the corresponding benign cystic neoplasm, often through an intermediate (borderline tumor) step, supporting the morphologic continuum of tumor progression.
  • Thus, it has been proposed that serous tumors arise from the implantation of epithelium (benign or malignant) from the fallopian tube.
  • As it is generally accepted that endometriosis develops from endometrial tissue by retrograde menstruation, it is reasonable to assume that the endometrium is the source of these ovarian neoplasms.


43. Krockenberger M, Engel JB, Schmidt M, Kohrenhagen N, Häusler SF, Dombrowski Y, Kapp M, Dietl J, Honig A: Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res; 2010 May;30(5):1653-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer.
  • The metabolic switch from oxidative glycolysis to non-oxidative fermentation of glucose and proteins performed by the tumor cells seems to be associated with TKTL1 and pAkt overexpression.
  • Therefore the aim of the present study was to investigate the expression of TKTL1 and pAkt in human specimens of endometrial cancer as compared to benign endometrium.
  • MATERIALS AND METHODS: Levels of TKTL1, pAkt, and GLUT1 expression were immunhistochemically evaluated on paraffin embedded biopsy material from 10 benign and 41 malignant endometrial tissue samples.
  • TKTL1 mRNA levels in the endometrial cancer cell lines Ishikawa and HEC-1A were evaluated by RT-PCR.
  • RESULTS: Expression of TKTL1, GLUT1 and pAKT was significantly increased in endometrial carcinomas as compared to benign endometrial tissue.
  • In the human endometrial cancer cell lines Ishikawa and HEC-1A, TKTL1 mRNA was clearly detectable.
  • CONCLUSION: The levels of TKTL1, GLUT1 and pAKT expression point to the glycolytic phenotype of malignant endometrial tissue.
  • Given the pronounced TKTL1 expression across all different subtypes of endometrial cancer, this protein could serve as a target for future cancer treatments.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Transketolase / biosynthesis
  • [MeSH-minor] Aged. Cell Line, Tumor. Female. Glucose / metabolism. Glucose Transporter Type 1 / metabolism. Glycolysis. Humans. Immunohistochemistry / methods. Middle Aged. Oxygen / chemistry. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592357.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / RNA, Messenger; 0 / SLC2A1 protein, human; EC 2.2.1.1 / TKTL1 protein, human; EC 2.2.1.1 / Transketolase; IY9XDZ35W2 / Glucose; S88TT14065 / Oxygen
  •  go-up   go-down


44. Dubé V, Grigull J, DeSouza LV, Ghanny S, Colgan TJ, Romaschin AD, Siu KW: Verification of endometrial tissue biomarkers previously discovered using mass spectrometry-based proteomics by means of immunohistochemistry in a tissue microarray format. J Proteome Res; 2007 Jul;6(7):2648-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Verification of endometrial tissue biomarkers previously discovered using mass spectrometry-based proteomics by means of immunohistochemistry in a tissue microarray format.
  • Here, we report results of a verification exercise involving six candidate endometrial cancer biomarkers previously discovered using mass-tagging and multidimensional liquid chromatography/tandem mass spectrometry (DeSouza L., et al. J.
  • A panel of the three best-performing biomarkers, chaperonin 10, pyruvate kinase M2, and alpha-1-antitrypsin, achieved a sensitivity of 0.85, specificity of 0.93, predictive value of 0.90, and positive predictive value of 0.88 in discriminating malignant from benign endometrium.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biomarkers, Tumor / standards. Endometrial Neoplasms / chemistry. Immunohistochemistry / methods. Tissue Array Analysis / methods
  • [MeSH-minor] Chromatography, Liquid. Endometrium / chemistry. Endometrium / pathology. Female. Humans. Mass Spectrometry. Proteomics / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17552551.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Zhai QJ, Ozcan A, Hamilton C, Shen SS, Coffey D, Krishnan B, Truong LD: PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol; 2010 Jul;18(4):323-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although PAX-2 is shown to be a sensitive marker for tumors derived from these organs, but whether it is specific, that is, whether other tumor types also express PAX-2, has not been systematically evaluated in either primary or metastatic tumors.
  • Among the non-neoplastic tissue, PAX-2 was expressed in glomerular parietal epithelial cells, renal collecting duct cells, atrophic renal tubular cells, epithelial cells of ovarian surface, fallopian tube, endocervix, endometrium, seminal vesicle, and lymphocytes.
  • Among the primary neoplasms, PAX-2 was noted in 104/122 (85%) of renal cell carcinoma, 31/95 carcinomas of Müllerian origin, 17/17 (100%) lymphomas, 4/4 (100%) nephrogenic adenomas, and 1/16 (6%) benign parathyroid tumors, but was negative in 477 other tumors.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216401.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor
  •  go-up   go-down


46. Carinelli S, Motta F, Frontino G, Restelli E, Fedele L: Multiple extrauterine adenomyomas and uterus-like masses: case reports and review of the literature. Fertil Steril; 2009 May;91(5):1956.e9-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENT(S): Two patients without urogenital malformations diagnosed with extrauterine adenomyoma, which is a benign tumor composed of smooth muscle and endometrium, typically originating within the uterus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19254794.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 19
  •  go-up   go-down


47. Nur S, Chuang L, Ramaswamy G: Immunohistochemical characterization of cancer antigen in uterine cancers. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1903-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pattern of cancer antigen (CA-125) expression by immunohistochemistry (IHC) was investigated in malignant and nonneoplastic endometrium in endometrial carcinoma.
  • Ninety cases of primary uterine carcinomas (65 endometrioid [EM] carcinoma, 15 serous papillary [SP] carcinoma, 6 carcinosarcomas [malignant mixed müllerian tumors], and 4 clear cell carcinoma [CC]) and adjacent atrophic and/or hyperplastic endometrium were analyzed by IHC for CA-125 expression.
  • SP carcinoma and endometrial intraepithelial carcinoma showed much higher mean IRS score than EM.
  • Benign proliferative glands showed moderate apical luminal, basal, and cytoplasmic staining.
  • Different patterns of CA-125 immunostaining were observed in normal, hyperplastic, and neoplastic endometrium.
  • The intense different staining pattern of endometrium with atypical complex hyperplasia suggests that CA-125 may be a useful diagnostic aid.
  • [MeSH-major] Adenocarcinoma / metabolism. CA-125 Antigen / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Mixed Tumor, Mullerian / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009990.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


48. Nassar A, Amin MB, Sexton DG, Cohen C: Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol; 2005 Sep;13(3):252-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, AMACR has been demonstrated to be overexpressed in localized and metastatic prostate cancer and in high-grade prostatic intraepithelial neoplasia but not in normal prostatic glands, suggesting that it may be an important tumor marker.
  • This study examines AMACR expression in a variety of human cancers to assess its viability as a tumor marker in the clinical setting.
  • Cancers studied included breast (94 cases), prostate (38), lung (28), endometrium (27), colon (29), ovary (26), and melanoma (21).
  • Normal tissues in the microarray were prostate (15), lung (6), endometrium (5), colon (4), ovary (2), and skin (3).
  • A section of prostate cancer and prostatic intraepithelial neoplasia was used as positive control.
  • AMACR protein overexpression was found in several cancers, including prostate (34/38 [89.5%]), colon (13/29 [44.8%]), lung (4/28 [14.3%]), melanoma (2/21 [9.5%]), endometrium (2/27 [7.4%]), and breast (3/94 [3.2%]).
  • AMACR expression was not present in any of the normal tissues nor in benign prostatic tissue associated with prostate carcinomas.
  • This study suggests that AMACR is potentially an important tumor marker, particularly for prostate and colon cancer.
  • It may be a useful adjunct to an immunohistochemical panel employed in the differential diagnosis of colon versus ovarian and breast carcinoma; the latter two infrequently express AMACR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082251.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


49. Robert Y, Bazot M: [Meno-metrorrhagia imaging]. J Radiol; 2008 Jan;89(1 Pt 2):115-33
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is the first-line technique examination for the identification of an etiology: benign endometrium lesion (polyp, endometrium atrophy or hypertrophy) or malignant tumor, myometrial lesions (adenomyosis, leiomyoma), adnexal tumors, and first trimester pregnancy complication.
  • Ultrasound gives orientation for diagnosis and therapeutic strategy.
  • [MeSH-major] Genital Diseases, Female / diagnosis. Magnetic Resonance Imaging. Menorrhagia / diagnosis. Menorrhagia / etiology. Metrorrhagia / diagnosis. Metrorrhagia / etiology. Ultrasonography, Doppler, Color
  • [MeSH-minor] Abortion, Spontaneous / diagnosis. Adult. Algorithms. Biopsy. Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / ultrasonography. Female. Humans. Hysterosalpingography. Hysteroscopy. Leiomyoma / diagnosis. Leiomyoma / ultrasonography. Menopause. Middle Aged. Polyps / ultrasonography. Pregnancy. Pregnancy, Ectopic / diagnosis. Uterine Diseases / diagnosis. Uterine Diseases / ultrasonography. Uterine Neoplasms / diagnosis. Uterine Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288038.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 49
  •  go-up   go-down


50. Dietz NK, Rehn M, Thanner F, Dietl J: [Diagnostic and preoperative staging of endometrial carcinoma with transvaginal sonography--a review]. Zentralbl Gynakol; 2006 Oct;128(5):246-54
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic and preoperative staging of endometrial carcinoma with transvaginal sonography--a review].
  • Endometrial carcinoma is the most common malignant tumor of the female genital tract.
  • Endometrial thickness (double layer) is measured by transvaginal sonography.
  • The cut-off value in patients with postmenopausal bleeding is still controversial, although in patients with endometrial thickness below 4 mm (or 5 mm respectively), malignancy can be excluded with high probability.
  • If the endometrium measures more than 4 mm (or more than 5 mm respectively) or the patient presents with continuous bleeding, hysteroscopy and curettage should be performed in order to obtain histologic diagnosis.
  • Sonographic findings like structure and demarcation of the endometrium increase diagnostic specificity only when combined with the measurement of endometrial thickness.
  • Measuring the fluid within the uterine cavity does not seem to be useful in differentiating malignant from benign disorders.
  • The extent of surgery depends on the preoperative estimation of the tumor stage which is particularly important for elder patients with increased morbidity.
  • This article on transvaginal ultrasound reviews current data on the method's capacity to identify endometrial cancer and to diagnose the depth of invasion.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Neoplasm Staging / methods. Ultrasonography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001559.001).
  • [ISSN] 0044-4197
  • [Journal-full-title] Zentralblatt für Gynäkologie
  • [ISO-abbreviation] Zentralbl Gynakol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 93
  •  go-up   go-down


51. Shah SS, Mazur MT: Endometrial eosinophilic syncytial change related to breakdown: immunohistochemical evidence suggests a regressive process. Int J Gynecol Pathol; 2008 Oct;27(4):534-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial eosinophilic syncytial change related to breakdown: immunohistochemical evidence suggests a regressive process.
  • Eosinophilic syncytial change (ESC), also known as papillary syncytial change, occurs in association with endometrial breakdown and bleeding, especially in nonphysiological conditions.
  • When prominent, this morphological alteration yields a pattern of eosinophilic epithelial cells, often in pseudopapillary arrangements that can mimic cellular changes seen in metaplastic and atypical endometrium.
  • Our methodology involved a retrospective immunohistochemical study on endometrial biopsies with proliferation markers Ki-67 (MIB-1 antibody) and phosphohistone H3 Ser 28 (pHH3) in 15 cases of multifocal ESC associated with benign endometrium, 5 cases of atypical hyperplasia, and 7 cases of endometrial carcinoma.
  • On immunohistochemical analysis, the Ki-67 labeling index was 1.3% for cases of ESC (mean age, 53 yr), 15.8% in atypical hyperplasia (mean age, 51.6 yr), and 42.6% in endometrial carcinoma (mean age, 68.1 yr).
  • In the endometrial cancers, the Ki-67 proliferative index was 10.6% for FIGO grade 1 tumors (n=3), 27.6% for grade 2 tumor (n=1), and 79.6% for serous carcinoma (n=3).
  • The mitotic index calculated from pHH3 immunostaining was zero in all cases of ESC, whereas it was 2.3% in atypical hyperplasia and 4.8% in endometrial carcinomas (2.4% for grade 1, 3% for grade 2, and 7.8% for serous).
  • Furthermore, when there is a question of whether eosinophilic endometrial epithelium represents this change, a combination of Ki-67 and pHH3 immunostains can be helpful in distinguishing this entity from more significant processes including carcinoma.
  • [MeSH-major] Endometrium / pathology. Eosinophils / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Cell Growth Processes / physiology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753967.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


52. Bradley WH, Lima PH, Rodgers L, Blomquist CH, Downs LS: Endometrial carcinoma expresses an increased cathepsin B/D ratio. Gynecol Oncol; 2008 Jan;108(1):84-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma expresses an increased cathepsin B/D ratio.
  • OBJECTIVES: Cathepsins B and D belong to a family of proteases involved in tumor invasion and metastasis.
  • As such they may function as biomarkers for the aggressiveness of a given tumor.
  • 4 groups were established: benign tissue, stage I/grade 1, stage i/grade 3, and stage IIIC/any grade.
  • RESULTS: A significantly increased level of cathepsin B activity was seen in malignant tissue specimens when compared to benign tissue.
  • The cathepsin B/D ratio confirmed and was required to detect the significance of this distinction for each malignant group when compared to benign samples.
  • CONCLUSIONS: Malignant endometrium displays increased cathepsin B activity when compared benign samples.
  • The cathepsin B/D ratio is increased for each of the malignant groups studied when compared directly to benign endometrium.
  • This ratio may serve to distinguish malignant from benign tumor samples and may be a constitutive change in the malignant transformation.
  • [MeSH-major] Cathepsin B / biosynthesis. Cathepsin D / biosynthesis. Endometrial Neoplasms / enzymology
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980407.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


53. Ahn HJ, Bae J, Lee S, Ko JE, Yoon S, Kim SJ, Sakuragi N: Differential expression of clusterin according to histological type of endometrial carcinoma. Gynecol Oncol; 2008 Aug;110(2):222-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of clusterin according to histological type of endometrial carcinoma.
  • Endometrial carcinoma is divided into endometrioid and papillary serous type carcinoma according to the histological characteristics and regarding to the unopposed estrogenic stimulation.
  • In this study, we investigated the expression profiles of clusterin according to the histological types and the effect of estrogen stimulation on its expression in endometrial carcinoma.
  • METHOD: Clusterin expression in endometrial carcinoma tissues was examined by RT-PCR, Western blot analysis, and immunohistochemistry.
  • The mRNA and protein expressions of clusterin in endometrioid carcinoma were higher than in benign endometrium (p=0.002).
  • CONCLUSIONS: These data suggest that clusterin expression is related to endometrioid carcinoma of endometrium, in which estrogen is involved in the regulatory network of clusterin.
  • [MeSH-major] Clusterin / biosynthesis. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Estradiol / pharmacology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Paraffin Embedding. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Stimulation, Chemical

  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18514801.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLU protein, human; 0 / Clusterin; 0 / RNA, Messenger; 4TI98Z838E / Estradiol
  •  go-up   go-down


54. Zhang XL, Zheng RQ, Yang YB, Huang DM, Song Q, Mao YJ, Li YH, Zheng ZJ: The use of contrast-enhanced ultrasound in uterine leiomyomas. Chin Med J (Engl); 2010 Nov;123(21):3095-9
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ultrasound (US) is a popular method in the diagnosis and treatment of uterine leiomyomas, but the lack of accuracy greatly limits its application.
  • Recently, microbubble enhancement technique affords direct depiction of tumor neovascularity and establishes a more precise vascular map of the tumor.
  • RESULTS: After contrast injection, vessels of macro- and micro-circulation of the myoma first appeared, followed by the normal myometrium and finally the endometrium.
  • The margin of the tumor was depicted clearly.
  • There was no agent perfusion in the benign degenerative or necrotic area.
  • In addition, the tumor exhibited heterogeneous hyperenhancment with no agent perfusion in the center and no membraniform sign was observed in the late phase.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21162962.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


55. Horn LC, Dallacker M, Bilek K: [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors]. Pathologe; 2009 Jul;30(4):292-301
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The strongest prognostic factor is tumor stage followed by lymph node metastases, deep myometrial infiltration, involvement of the cervix and tumor size.
  • Clinical and pathologic staging should be performed as in endometrial carcinoma.
  • The main differential diagnoses include uterine sarcomas, adenosarcoma and benign metaplastic change within the endometrium.
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Cervix Uteri / pathology. Female. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Myometrium / pathology. Neoplasm Staging. Prognosis. Survival Rate. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Dec;6(12):961-71 [16321764.001]
  • [Cites] Gynecol Oncol. 1997 Dec;67(3):316-21 [9441781.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):274-80 [15972232.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2782-6 [10870061.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):684-7 [16797683.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):3069-74 [11712812.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):321-5 [11986333.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):786-96 [14967435.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):75-82 [12496702.001]
  • (PMID = 19495763.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Shen SH, Chiou YY, Wang JH, Yen MS, Lee RC, Lai CR, Chang CY: Diffusion-weighted single-shot echo-planar imaging with parallel technique in assessment of endometrial cancer. AJR Am J Roentgenol; 2008 Feb;190(2):481-8
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted single-shot echo-planar imaging with parallel technique in assessment of endometrial cancer.
  • OBJECTIVE: The purposes of this study were to determine the feasibility of diffusion-weighted imaging (DWI) with a single-shot echo-planar sequence and parallel technique for depicting endometrial cancer and to examine the role of this technique in preoperative assessment.
  • SUBJECTS AND METHODS: A total of 31 patients were recruited for MRI evaluation of suspicious endometrial lesions found on transvaginal sonography.
  • Twenty-four of the patients were proved to have endometrial cancer (patient group), and seven to have benign diseases (control group).
  • The apparent diffusion coefficient of endometrial cancer in the patient group and of normal endometrium in the control group were measured on the apparent diffusion coefficient map of each diffusion-weighted image and compared for the two groups.
  • RESULTS: The mean apparent diffusion coefficient of endometrial cancer was 0.864 x 10(-3) mm2/s and that of benign endometrial lesions was 1.277 x 10(-3) mm2/s.
  • In five cases, DWI provided information about tumor extent and depicted the tumor focus, findings that changed preoperative staging.
  • CONCLUSION: DWI performed with parallel imaging technique has potential as a method for differentiating benign from malignant endometrial lesions.
  • It also provides valuable information for preoperative evaluation and should be considered part of routine preoperative MRI evaluation for endometrial cancer.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Echo-Planar Imaging / methods. Endometrial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212236.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Fleming NA, Hopkins L, de Nanassy J, Senterman M, Black AY: Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature. J Pediatr Adolesc Gynecol; 2009 Aug;22(4):e45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Müllerian adenosarcoma is a rare neoplasm usually found in postmenopausal women.
  • It usually presents as a polypoid mass within the endometrium.
  • It is a biphasic tumor, composed of a benign epithelial component and a malignant stromal component.
  • To date, this neoplasm has been reported in only 16 adolescent girls.
  • An endometrial curettage was performed.
  • Pathology confirmed a diagnosis of müllerian adenosarcoma originating from the endocervix.
  • After a thorough evaluation of the available literature, review with the Regional Tumor Board and extensive discussions with the family, a decision was made to perform a radical hysterectomy, bilateral salpingectomy, bilateral pelvic lymph node dissection, upper vaginectomy and preservation of ovaries.
  • CONCLUSION: Müllerian adenosarcoma of the endocervix is a very rare pediatric tumor.
  • Due to the rarity of this tumor in this age group, optimal therapy is uncertain.


58. Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, Estellés A: Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem; 2008;15(9):923-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The fibrinolytic system includes a broad spectrum of proteolytic enzymes with physiological and pathophysiological functions in several processes, such as haemostatic balance, tissue remodeling, tumor invasion, angiogenesis and reproduction.
  • Indeed, studies of several types of cancers, including breast cancer, have shown that increased uPA and PAI-1 levels are associated with aggressive tumor behavior and poor prognosis.
  • Endometriosis is defined by the presence of endometrial glands and stroma outside the uterus with marked ability to attach and invade the peritoneum.
  • It is one of the most frequent benign gynecological diseases that affect women with pelvic pain or infertility during their reproductive age.
  • Immune system disorders, genetic predisposition, altered peritoneal environment and endometrial alterations are believed to increase the susceptibility to endometriosis.
  • Altered expression of several components of the fibrinolytic system in both eutopic and ectopic endometrium and peritoneal fluid of women with the disease has been implicated not only in the onset, but also in the progression of the endometriotic lesions.

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473800.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Plasminogen Inactivators; 9001-31-4 / Fibrin; 9001-91-6 / Plasminogen; EC 3.4.21.- / Plasminogen Activators; EC 3.4.21.68 / Tissue Plasminogen Activator; EC 3.4.21.7 / Fibrinolysin; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 163
  •  go-up   go-down


59. Jarboe EA, Pizer ES, Miron A, Monte N, Mutter GL, Crum CP: Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol; 2009 Mar;22(3):345-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma.
  • Both serous intraepithelial carcinoma and endometrial glandular dysplasia are associated with uterine serous carcinoma.
  • We analyzed normal and neoplastic endometrium for a similar entity.
  • In total 10 endometrial polyps involved by intraepithelial and/or invasive carcinoma and 137 benign polyps were studied.
  • Of 137 benign polyps (4%), 6 contained p53 signatures.
  • DNA damage (gamma-H2AX) was demonstrated in both p53 signatures and adjacent carcinomas but not in benign polyps.
  • The significance of p53 signatures in benign conditions (polyps) remains to be determined.
  • The role of the p53 signature in early serous neoplasia is discussed.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2263-9 [18369088.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):937-42 [18500258.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):226-32 [18718648.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1467-71 [10550302.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Obstet Gynecol. 1987 Jan;69(1):109-13 [3796910.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):617-22 [15949437.001]
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1327-34 [16319259.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Gynecol Oncol. 2007 Jan;104(1):7-10 [16962648.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • (PMID = 19151662.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA105009-05; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / R21 CA124688-02; United States / NCI NIH HHS / CA / R21 CA124688; United States / NCI NIH HHS / CA / K08 CA108748; United States / NCI NIH HHS / CA / CA124688-02; United States / NCI NIH HHS / CA / 1R21CA124688-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / H2AFX protein, human; 0 / Histones; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS77435; NLM/ PMC2649686
  •  go-up   go-down


60. Van Patten K, Parkash V, Jain D: Cadherin expression in gastrointestinal tract endometriosis: possible role in deep tissue invasion and development of malignancy. Mod Pathol; 2010 Jan;23(1):38-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases of normal proliferative and secretory endometrium and adenomyosis were included in the study for comparison.
  • Compared with normal proliferative endometrium, N-cadherin expression was decreased in intensity and extent in secretory endometrium.
  • Peritoneal and gastrointestinal endometriosis also showed markedly decreased expression of N-cadherin compared with proliferative endometrium.
  • All three cases of carcinoma arising in colonic endometriosis showed a total loss of N-cadherin in the tumor, but preserved E-cadherin and beta-catenin expression.
  • In these cases, areas of benign endometriotic glands near the tumor showed weak and focal N-cadherin expression that was gradually lost.
  • Moderate-to-strong membranous staining for beta-catenin expression and variable intensity of E-cadherin expression was seen diffusely in normal endometrium and all study cases.
  • [MeSH-major] Cadherins / biosynthesis. Cell Transformation, Neoplastic / metabolism. Endometrial Neoplasms / metabolism. Endometriosis / metabolism. Gastrointestinal Diseases / metabolism

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898423.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


61. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol; 2010;8:147
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.
  • BACKGROUND: Recent data provide significant evidence to support the hypothesis that there are sub-populations of cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
  • CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas, ovary and endometrium.
  • Our objectives were to assess the relative level of CD133 expressing cells in primary human endometrial tumors, confirm their tumorigenic potential, and determine whether CD133 expression was epigenetically modified.
  • METHODS: We assessed CD133 expression in primary human endometrial tumors by flow cytometry and analyzed the relative tumorigenicity of CD133+ and CD133- cells in an in vivo NOD/SCID mouse model.
  • We further examined CD133 promoter methylation and expression in normal endometrium and malignant tumors.
  • RESULTS: As determined by flow cytometric analysis, the percentage of CD133+ cells in primary human endometrial cancer samples ranged from 5.7% to 27.4%.
  • In addition, we confirmed the tumor initiating potential of CD133+ and CD133- cell fractions in NOD/SCID mice.
  • Interestingly, the percentage of CD133+ cells in human endometrial tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend was not consistently detected by flow cytometry.
  • We also determined that the relative levels of CD133 increased in endometrial cancer cell lines following treatment with 5-aza-2'-deoxycytidine suggesting a role for methylation in the regulation of CD133.
  • To support this finding, we demonstrated that regions of the CD133 promoter were hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue.
  • Lastly, we determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor xenograft.
  • CONCLUSIONS: These findings support the hypotheses that CD133 expression in endometrial cancer may be epigenetically regulated and that cell fractions enriched for CD133+ cells may well contribute to endometrial cancer tumorigenicity, pathology and recurrence.
  • [MeSH-major] Antigens, CD / genetics. Cell Transformation, Neoplastic / pathology. Endometrial Neoplasms / pathology. Epigenomics. Glycoproteins / genetics. Neoplastic Stem Cells / pathology. Peptides / genetics
  • [MeSH-minor] Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Oct;18(10):1037-46 [18679414.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8094-103 [18829568.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Biol Reprod. 2009 Jun;80(6):1136-45 [19228591.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2235-7 [19528487.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [19509143.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8241-8 [19843861.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2405-13 [19658191.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] J Biochem. 2010 Sep;148(3):273-80 [20551139.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1516-29 [20800872.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):227-42 [11174845.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1738-50 [14766732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Biol Reprod. 1989 Mar;40(3):681-90 [2758097.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):45-51 [16923745.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1214-23 [17283036.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 [17868344.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • (PMID = 21122138.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3027593
  •  go-up   go-down


62. Kefeli M, Gonullu G, Can B, Malatyalioglu E, Kandemir B: Metastasis of adenocarcinoma of the gall bladder to an endometrial polyp detected by endometrial curettage: case report and review of the literature. Int J Gynecol Pathol; 2009 Jul;28(4):343-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of adenocarcinoma of the gall bladder to an endometrial polyp detected by endometrial curettage: case report and review of the literature.
  • SUMMARY: Polyps are the most common benign lesions in the endometrium.
  • Metastasis to the endometrial polyp from a distant primary tumor is rare.
  • Breast carcinoma is the most frequent extragenital cancer that metastasizes to the endometrial polyp.
  • We report the case of a 63-year-old with metastatic gall bladder adenocarcinoma involving endometrial polyps detected by endometrial curetting.
  • After this diagnosis, bone metastases were detected during radiologic screening.
  • Gastrointestinal tumor metastasis to an endometrial polyp is a very rare event, but if a patient with a known primary extragenital tumor has abnormal vaginal bleeding, the possibility of metastasis should be included in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / secondary. Gallbladder Neoplasms / pathology. Polyps / pathology
  • [MeSH-minor] Aged. Dilatation and Curettage. Female. Humans. Immunohistochemistry. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483630.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


63. Andikyan V, Taylor HS: WT1 represses HOX gene expression in the regulation of gynaecologic tumour histologic type. J Cell Mol Med; 2009 Nov-Dec;13(11-12):4522-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified a strong inverse correlation between HOXA10 expression and that of the Wilms' Tumour 1 (WT1) gene in multiple benign and malignant gynaecologic tissues, suggesting functionality of the WT1 sites in the repressor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):449-55 [15297187.001]
  • [Cites] Endocrinology. 2004 May;145(5):2291-6 [14726435.001]
  • [Cites] Nature. 1978 Dec 7;276(5688):565-70 [103000.001]
  • [Cites] Nature. 1990 Jul 12;346(6280):194-7 [2164159.001]
  • [Cites] Cell. 1992 Jan 24;68(2):283-302 [1346368.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2445-53 [1358259.001]
  • [Cites] Oncogene. 1992 Nov;7(11):2141-9 [1331933.001]
  • [Cites] Mech Dev. 1993 Jan;40(1-2):85-97 [8382938.001]
  • [Cites] Cell. 1994 Jul 29;78(2):191-201 [7913880.001]
  • [Cites] Nature. 1995 Mar 30;374(6521):460-3 [7700356.001]
  • [Cites] Development. 1995 May;121(5):1373-85 [7789268.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):284-9 [8673126.001]
  • [Cites] Dev Dyn. 1997 Apr;208(4):454-65 [9097018.001]
  • [Cites] Biol Reprod. 1997 Dec;57(6):1338-45 [9408238.001]
  • [Cites] Hum Mol Genet. 1998 Apr;7(4):709-14 [9499425.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1379-84 [9525980.001]
  • [Cites] Curr Opin Genet Dev. 1998 Aug;8(4):423-9 [9729718.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):437-42 [10053122.001]
  • [Cites] Hum Reprod. 1999 May;14(5):1328-31 [10325287.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):522-8 [15494461.001]
  • [Cites] Nat Med. 2005 May;11(5):531-7 [15821746.001]
  • [Cites] Pediatrics. 2005 Oct;116(4):984-8 [16199712.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2428-37 [16199152.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):889-97 [16424022.001]
  • [Cites] Int J Gynecol Pathol. 2000 Apr;19(2):158-63 [10782413.001]
  • [Cites] Biochem Pharmacol. 1999 Dec 15;58(12):1851-7 [10591139.001]
  • [Cites] Reprod Sci. 2007 Sep;14(6):605-14 [17959889.001]
  • [Cites] Semin Reprod Med. 2000;18(1):81-9 [11299523.001]
  • [Cites] Pediatr Nephrol. 2001 Apr;16(4):335-9 [11354777.001]
  • [Cites] Gene. 2001 Aug 8;273(2):141-61 [11595161.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Sep 10;110(1):111-3 [12932885.001]
  • [Cites] Cancer Biol Ther. 2004 Jun;3(6):568-72 [15044858.001]
  • (PMID = 19017365.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD036887; United States / NICHD NIH HHS / HD / R29 HD036887; United States / NICHD NIH HHS / HD / U54 HD052668-05; United States / NICHD NIH HHS / HD / U54 HD052668; United States / NICHD NIH HHS / HD / HD062668; United States / NICHD NIH HHS / HD / R01 HD036887
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Repressor Proteins; 0 / WT1 Proteins; 140441-81-2 / HOXA10 protein, human
  • [Other-IDs] NLM/ NIHMS293627; NLM/ PMC3107857
  •  go-up   go-down


64. Tamai K, Togashi K, Ito T, Morisawa N, Fujiwara T, Koyama T: MR imaging findings of adenomyosis: correlation with histopathologic features and diagnostic pitfalls. Radiographics; 2005 Jan-Feb;25(1):21-40
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomyosis is a nonneoplastic condition, characterized by benign invasion of ectopic endometrium into the myometrium with hyperplasia of adjacent smooth muscle.
  • The common symptoms include dysmenorrhea, menorrhagia, and abnormal uterine bleeding, but these do not allow diagnosis.
  • Therefore, imaging plays an important role because establishment of the correct preoperative diagnosis is critical to avoid unnecessary intervention.
  • Magnetic resonance (MR) imaging is a highly accurate noninvasive modality for diagnosis of adenomyosis, differentiation of adenomyosis from other gynecologic disorders, and planning of appropriate treatment.
  • Furthermore, malignancy occasionally develops in otherwise benign adenomyosis.
  • Pitfalls in diagnosis of adenomyosis include myometrial contractions, leiomyoma, adenomatoid tumor, metastases, endometrial carcinoma, and endometrial stromal sarcoma.
  • Knowledge of the various appearances of adenomyosis and the possible pitfalls in differential diagnosis help guide the determination of appropriate treatment options.
  • [MeSH-major] Endometriosis / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2005.
  • (PMID = 15653584.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


65. Kimmich T, Brüning A, Käufl SD, Makovitzky J, Kuhn C, Jeschke U, Friese K, Mylonas I: Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line. Arch Gynecol Obstet; 2010 Aug;282(2):185-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line.
  • However, only limited data on the expression of these novel inhibin subunits in normal human endometrial tissue and endometrial adenocarcinoma cell lines exist.
  • MATERIALS AND METHODS: Samples of proliferative and secretory human endometrium were obtained from five premenopausal, non-pregnant patients undergoing gynecological surgery for benign diseases.
  • Normal endometrial tissue and Ishikawa endometrial adenocarcinoma cell lines were analyzed by immunohistochemistry, immunofluorescence and RT-PCR.
  • RESULTS: Expression of the inhibin betaC and betaE subunits could be demonstrated at the protein level by means of immunohistochemical evaluation and at the transcriptional level by establishing a betaC- and betaE-specific RT-PCR analysis in normal human endometrial tissue and the parental Ishikawa cell line.
  • DISCUSSION: Here, we show for the first time that the novel inhibin/activin-betaC and -betaE subunits are expressed in normal human endometrium and the estrogen receptor positive human endometrial carcinoma cell line Ishikawa using RT-PCR and immunohistochemical detection methods.
  • Interestingly, the Ishikawa minus cell line (lacking estrogen receptor expression) demonstrated no to minimal expression of the betaC subunit as observed with immunofluorescence and RT-PCR, suggesting a possible hormone- dependency of this subunit in human endometrial cancer cells.
  • Moreover, because the Ishikawa cell line minus is thought to be a more malignant endometrial cell line than its estrogen receptor positive counterpart, inhibin-betaC subunit might be substantially involved in the pathogenesis and malignant transformation in human endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Inhibin-beta Subunits / biosynthesis
  • [MeSH-minor] Cell Dedifferentiation. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Receptors, Estrogen / analysis. Receptors, Estrogen / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012305.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / INHBC protein, human; 0 / INHBE protein, human; 0 / Receptors, Estrogen; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


66. Ip PP, Lam KW, Cheung CL, Yeung MC, Pun TC, Chan QK, Cheung AN: Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas. Am J Surg Pathol; 2007 Aug;31(8):1215-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Women with menorrhagia have increased levels of plasminogen activators in the endometrium.
  • When the overall gross and microscopic features of a leiomyoma with coagulative necrosis favor a benign lesion, the drug history should be reviewed so that this type of early and healing infarct-type necrosis is considered as the underlying cause of the apparent coagulative necrosis.
  • This may otherwise result in a diagnosis of smooth muscle tumor of uncertain malignant potential, leading to prolonged follow-up and unnecessary further surgical intervention.

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667546.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifibrinolytic Agents; 6T84R30KC1 / Tranexamic Acid
  •  go-up   go-down


67. Tahlan A, Nanda A, Mohan H: Uterine adenomyoma: a clinicopathologic review of 26 cases and a review of the literature. Int J Gynecol Pathol; 2006 Oct;25(4):361-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomyoma of the uterus is a circumscribed nodular aggregate of benign endometrial glands surrounded by endometrial stroma with leiomyomatous smooth muscle bordering the endometrial stromal component.
  • It may be located within the myometrium, or it may involve or originate in the endometrium and grow as a polyp.
  • The criterion used for case identification was a circumscribed mass composed of benign endometrial glands with a stromal component consisting of endometrial type stroma surrounded by leiomyomatous smooth muscle.
  • Thirteen patients underwent panhysterectomy; 7, total hysterectomy; 1, subtotal hysterectomy; 4, polypectomy or tumor removal; and 1, curettage.
  • The endometrial glands were mostly tubular and showed relatively regular spacing from each other without any back-to-back arrangement.
  • The glands were lined by benign proliferative pseudostratified columnar epithelium.
  • The glands were surrounded by endometrial stroma which was compact and spindly.
  • One to two typical mitotic figures per 10 hpf were noted in the endometrial stroma in few cases; however, no mitosis was noted in the myometrial component.
  • Adenomyomas have to be distinguished from a number of other lesions, for example, adenomyosis, leiomyoma with entrapped glands, atypical polypoid adenomyoma, endometrial polyps, adenofibroma, and adenosarcoma.
  • This study highlights the importance of correctly identifying this fairly common entity and helps to distinguish adenomyoma from other similar appearing benign and malignant lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990713.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


68. Yi N, Liao QP, Li T, Xiong Y: Novel expression profiles and invasiveness-related biology function of DKK1 in endometrial carcinoma. Oncol Rep; 2009 Jun;21(6):1421-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel expression profiles and invasiveness-related biology function of DKK1 in endometrial carcinoma.
  • In this study, we showed that in benign and malignant endometrium, DKK1 exhibited novel expression profiles and invasiveness-related biology function: DKK1 was expressed in both glandular epithelium and matrix of two kinds of endometrium tissues and mostly distributed in the cytoplasm and epicytes of endometrial carcinoma (EC) Ishikawa cell line.
  • DKK1 expression level in EC was significantly lower than that in benign endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Intercellular Signaling Peptides and Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Cell Movement. Down-Regulation. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Signal Transduction. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424619.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / beta Catenin
  •  go-up   go-down


69. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol; 2009 Jun;22(6):824-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glypican-3 is a heparan sulfate proteoglycan that is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor.
  • Glypican-3 is currently regarded as a tumor marker and potential target for immunotherapy.
  • To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Müllerian duct derivatives including endometrium in different menstrual phases.
  • Among the benign lesions examined, glypican-3 expression was identified exclusively in the endometrial epithelium in the gestational period.
  • In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Glypicans / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329941.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


70. Granovsky-Grisaru S, Zaidoun S, Grisaru D, Yekel Y, Prus D, Beller U, Bar-Shavit R: The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol Oncol; 2006 Dec;103(3):802-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma.
  • While the role of either soluble or matrix-immobilized protease in tumor invasion is well established, the part of cell surface PARs is beginning to emerge.
  • We sought to investigate the expression pattern of Protease Activated Receptor 1 (hPar1) in endometrial carcinoma, the most common type of gynecological malignancy.
  • METHODS: Tissue biopsy specimens taken from seventy-four formalin-fixed, paraffin-embedded endometrial tissue blocks were obtained from archival material.
  • RESULTS: The levels of hPar1 mRNA and protein were high and abundant in high-grade endometrial carcinoma, regardless of the histological subtype.
  • In contrast, no hPar1 was detected in endometrial epithelia with conserved glandular structure represented by normal, hyperplastic or low-grade carcinomas.
  • CONCLUSIONS: PAR1 over-expression is selectively confined to the highly aggressive, high-grade endometrial carcinoma and absent in tissue obtained from benign endometrium or low-grade endometrial cancer.
  • This finding highlights the significance of hPar1 gene involvement in invasive endometrial carcinoma and appoints it an attractive candidate for anti-cancer therapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Receptor, PAR-1 / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging. RNA, Messenger / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875721.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptor, PAR-1
  •  go-up   go-down


71. Deng L, Broaddus RR, McCampbell A, Shipley GL, Loose DS, Stancel GM, Pickar JH, Davies PJ: Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. Clin Cancer Res; 2005 Dec 1;11(23):8258-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer.
  • Here, we describe the expression pattern of a novel estrogen-induced gene, EIG121, in distinct types of endometrial cancer.
  • EXPERIMENTAL DESIGN: EIG121 was identified by cDNA microarray analysis of endometrial RNA from women receiving either placebo or estrogen replacement therapy.
  • The expression level of EIG121 was then measured by real-time quantitative reverse transcription-PCR in benign, hyperplastic, and malignant endometrial samples.
  • RESULTS: In postmenopausal endometrium, estrogen replacement therapy with Premarin and synthetic estrogen sulfate conjugates induced the expression of EIG121 2- and 3-fold, respectively.
  • In premenopausal endometrium, the expression of EIG121 was higher in the estrogen-dominated proliferative phase than the secretory phase.
  • In endometrial complex, hyperplasia, and endometrioid adenocarcinoma, neoplastic proliferations associated with estrogen excess, the expression of EIG121 was significantly elevated (on average 3.8-fold in hyperplasias and 21-fold in grade 1 tumors).
  • Although the level of EIG121 mRNA in grade 3 endometrioid carcinoma was still 3.5-fold of that in benign endometrium, EIG121 expression tended to decline with increasing tumor grade and disease stage.
  • Immunohistochemistry showed faint staining of normal endometrial epithelium, but intense staining of endometrioid tumors.
  • In sharp contrast, EIG121 expression was significantly suppressed in both uterine papillary serous carcinoma and uterine malignant mixed mullerian tumor, two tumors not associated with estrogen exposure, to <5% of the level in benign endometrium.
  • CONCLUSIONS: Our results suggest that EIG121 is a good endometrial biomarker associated with a hyperestrogenic state and estrogen-related type I endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Endometrial Neoplasms / genetics. Estrogen Replacement Therapy. Estrogens / therapeutic use. Gene Expression Regulation, Neoplastic / drug effects. Neoplasm Proteins / genetics
  • [MeSH-minor] Case-Control Studies. Endometrial Hyperplasia / genetics. Endometrial Hyperplasia / pathology. Estrogens, Conjugated (USP) / therapeutic use. Estrone / analogs & derivatives. Estrone / therapeutic use. Expressed Sequence Tags. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRONE .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322283.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NICHD NIH HHS / HD / 5T32 HD007324-18
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogens; 0 / Estrogens, Conjugated (USP); 0 / KIAA1324 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 2DI9HA706A / Estrone; QTL48N278K / estrone sulfate
  •  go-up   go-down


72. Abiko K, Baba T, Ogawa M, Mikami Y, Koyama T, Mandai M, Konishi I: Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus. Pathol Int; 2010 Jan;60(1):42-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary mucinous adenocarcinomas of the uterine corpus are typically low grade and frequently associated with endometrial hyperplasia and/or ordinary endometrioid adenocarcinoma, but may appear as a heterogeneous group of neoplasms.
  • In some areas endometrial glands of adenomyosis were replaced by benign-looking mucinous metaplasia.
  • HIK1083 and MUC6 immunohistochemistry indicated a gastric phenotype of the tumor, as seen in cases of prototypical minimal deviation adenocarcinoma (MDA) of the cervix.
  • In summary, mucinous endometrial adenocarcinoma rarely shows features similar to MDA of the cervix.
  • This case provokes a discussion on diagnostic and management strategy, and histogenesis of mucinous neoplasm of the endometrium.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055951.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


73. Yoshizaki T, Enomoto T, Nakashima R, Ueda Y, Kanao H, Yoshino K, Fukumoto M, Yoneda Y, Buzard GS, Murata Y: Altered protein expression in endometrial carcinogenesis. Cancer Lett; 2005 Aug 26;226(2):101-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered protein expression in endometrial carcinogenesis.
  • We have discovered several protein biomarkers that are altered during carcinogenesis of the human uterine endometrium.
  • Proteins prepared from 19 endometrial carcinomas (Group A), and 20 normal endometria obtained from benign gynecological conditions (Group B), were investigated by Surface Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS).
  • These proteins are thus potential biomarkers for detection of endometrial carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039949.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


74. Strissel PL, Ellmann S, Loprich E, Thiel F, Fasching PA, Stiegler E, Hartmann A, Beckmann MW, Strick R: Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen. Int J Cancer; 2008 Dec 15;123(12):2871-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen.
  • In addition to the beneficial effect, tamoxifen is one risk factor for endometrial carcinoma (EnCa) development.
  • We hypothesized that, (1) dysregulation of gene expression and protein phosphorylation of the insulin-like growth factor (IGF) and steroid hormone receptor-signaling occur early in benign endometrial tissues and (2) signaling differences would be detected between patients with or without tamoxifen treatment.
  • Seventy-eight tissues, including 2 benign cohorts from patients treated with (n = 24) or without tamoxifen (n = 28) (hyperproliferative endometrium, hyperplasia, polyps), EnCa (n = 12) with endometrium controls (n = 14) were analyzed for expression of 15 genes from the IGF and steroid hormone receptor-signaling, including the target genes Syncytin-1, PAX2 and c-myc.
  • Compared to controls similar significant deregulation of IGF and steroid hormone receptor-signaling, Syncytin-1 and PAX2 occurred in both benign cohorts, irrelevant of tamoxifen treatment.
  • Comparing both benign cohorts with and without tamoxifen significant expression differences were noted.
  • Increased total protein and phosphorylation of pERalpha-Ser118, pPTEN-Thr380, pAKT-Thr308, pAKT-Ser473, pmTOR-Ser2448 and Syncytin-1 were noted in early benign tissue stages associating with tamoxifen, especially polyps.
  • This study supports that dysregulated IGF and steroid hormone receptor signaling is prominent in endometrial benign stages and these alterations could represent clinical indicators for the risk of EnCa and also help in development of new therapies.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Biomarkers, Tumor / metabolism. Carcinoma / etiology. Endometrial Neoplasms / etiology. Estrogen Receptor Modulators / adverse effects. Insulin-Like Growth Factor I / metabolism. Tamoxifen / adverse effects

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18814240.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor Modulators; 0 / Gonadal Steroid Hormones; 094ZI81Y45 / Tamoxifen; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


75. Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, Fischer AH: Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol; 2007 Dec;20(12):1263-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
  • To investigate the diagnostic and clinicopathologic significance of this protein in endometrial carcinomas, we evaluated immunohistochemical expression of IMP3 in the two most common forms of endometrial malignancies, endometrioid adenocarcinoma and serous carcinoma.
  • We selected 167 endometrial adenocarcinoma cases including 122 cases of endometrioid adenocarcinoma and 45 cases of serous carcinoma.
  • Twenty samples of benign endometrium obtained from 20 patients with nonmalignant uterine lesions were used as controls.
  • Positive immunohistochemical stain for IMP3 was identified in all serous carcinoma cases, among which, 39 (86%) and 3 (7%) cases showed IMP3 immunoreactivity in >50%, and 21-50, or 6-20% of tumor cells, respectively.
  • Thirty (25%), 20 (16%), 10 (8%), and 8 (7%) cases of endometrioid adenocarcinoma demonstrated positive immunoreactivity for IMP3 in 1-5, 6-20, 21-50, and >50% of the tumor cells.
  • To compare p53 with IMP3 expressions, we found that 35 (78%) of the serous carcinoma cases showed strong p53 immunohistochemical activity in >50% of the tumor cell nuclei.
  • In contrast, 11 of 112 (10%) endometrioid adenocarcinoma cases demonstrated strong p53 positivity in >50% of the tumor cell nuclei.
  • Expression of IMP3 and p53 may be helpful biomarkers in the distinction of endometrial serous carcinoma from endometrioid adenocarcinoma.
  • In addition, expression of IMP3 in endometrioid adenocarcinoma correlates with higher nuclear and architecture grades of the tumor (P=0.0000 and P=0.0002, respectively).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / biosynthesis. Diagnosis, Differential. Female. Gene Expression. Humans. Immunohistochemistry. Middle Aged. Tumor Suppressor Protein p53 / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885673.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / oncofetal antigens
  •  go-up   go-down


76. Li X, Qi X, Zhou L, Catera D, Rote NS, Potashkin J, Abdul-Karim FW, Gorodeski GI: Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells. Gynecol Oncol; 2007 Jul;106(1):233-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells.
  • OBJECTIVES: To understand the potential role of P2X(7) as biomarker of endometrial cancer, and the molecular mechanisms by which cancerous epithelial cells maintain low expression of P2X(7).
  • Normal (28), simple or complex hyperplasia (7), complex hyperplasia with atypia (6) and cancer endometrial discarded tissues (40) were obtained from a total of 81 women, ages 25-75.
  • RESULTS: Levels of P2X(7) protein and mRNA were significantly lower in vivo, in tissues of complex hyperplasia with atypia or endometrial adenocarcinoma, than in tissues of normal endometrium, simple hyperplasia or complex hyperplasia tissues (sensitivity and specificity of 89-100%, p<0.0001-0.01).
  • CONCLUSIONS: Tissue levels of P2X(7) protein and mRNA can differentiate effectively and accurately between normal and benign hyperplastic endometrial tissues from pre-cancerous and cancer tissues.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Br J Pharmacol. 1999 Aug;127(8):1915-21 [10482924.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5568-79 [15319352.001]
  • [Cites] Endocrinology. 2005 Jan;146(1):164-74 [15459114.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jun;288(6):C1342-56 [15728711.001]
  • [Cites] Obstet Gynecol. 2005 Aug;106(2):413-25 [16055605.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):388-92 [16051336.001]
  • [Cites] Public Health Nutr. 2005 Oct;8(7):912-9 [16277808.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):812-9 [16400639.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):804-11 [16400640.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):729-31 [16400641.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):363-77 [16364689.001]
  • [Cites] Hum Reprod. 2006 Apr;21(4):924-9 [16361289.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):17228-37 [16624800.001]
  • [Cites] Am J Epidemiol. 2006 Jul 1;164(1):56-62 [16675538.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1906-13 [17035398.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1765-72 [11042572.001]
  • [Cites] Gene. 2001 Mar 7;265(1-2):11-23 [11255003.001]
  • [Cites] Curr Opin Cell Biol. 2001 Jun;13(3):320-5 [11343902.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4590-6 [12464620.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Nov;287(5):C1349-58 [15269006.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Differentiation. 1994 Apr;56(1-2):107-18 [7517899.001]
  • (PMID = 17482244.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG015955-03; United States / NIA NIH HHS / AG / AG015955-06; United States / NIA NIH HHS / AG / AG015955-05; United States / NIA NIH HHS / AG / AG015955-09; United States / NIA NIH HHS / AG / R01 AG015955-06; United States / NIA NIH HHS / AG / AG015955-04; United States / NIA NIH HHS / AG / R01 AG015955-05; United States / NIA NIH HHS / AG / R01 AG015955-02; United States / NIA NIH HHS / AG / R01 AG015955-07; United States / NIA NIH HHS / AG / AG015955-07; United States / NIA NIH HHS / AG / AG015955-03; United States / NIA NIH HHS / AG / R01 AG015955-01A1; United States / NIA NIH HHS / AG / AG015955-02; United States / NIA NIH HHS / AG / AG15955; United States / NIA NIH HHS / AG / R01 AG015955-04; United States / NIA NIH HHS / AG / R01 AG015955-08; United States / NIA NIH HHS / AG / AG015955-08; United States / NIA NIH HHS / AG / AG015955-01A1; United States / NIA NIH HHS / AG / R01 AG015955; United States / NIA NIH HHS / AG / R01 AG015955-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / P2RX7 protein, human; 0 / RNA, Messenger; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X7
  • [Other-IDs] NLM/ NIHMS47290; NLM/ PMC2398694
  •  go-up   go-down


77. Redman R, Wilkinson EJ, Massoll NA: Uterine-like mass with features of an extrauterine adenomyoma presenting 22 years after total abdominal hysterectomy-bilateral salpingo-oophorectomy: a case report and review of the literature. Arch Pathol Lab Med; 2005 Aug;129(8):1041-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomyoma is a benign tumor composed of smooth muscle and benign endometrium.
  • The mass was pear-shaped with uterine-type smooth muscle and a cavity lined by functional endometrial glands and stroma.
  • The presence of endometrial glands and stroma in the mass confirms that the tissues in this mass are hormonally responsive.
  • [MeSH-major] Adenomyoma / pathology. Gynecologic Surgical Procedures. Neoplasms, Hormone-Dependent / diagnosis. Uterine Neoplasms / pathology. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048397.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Li S, Meng L, Zhu C, Wu L, Bai X, Wei J, Lu Y, Zhou J, Ma D: The universal overexpression of a cancer testis antigen hiwi is associated with cancer angiogenesis. Oncol Rep; 2010 Apr;23(4):1063-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The difference of mRNA expression in blood vessels derived from DLBCL and RLNH tissues was detected, and hiwi was overexpressed in tumor vessels of lymphoma.
  • Compared with that of chronic cervicitis (CC), hyperplasia of mammary glands (HMG), ovarian benign lesions (OBL) and endometrium benign lesions (EBL), the expression of hiwi, Ang-2 and Tie-2 was increased significantly in uterine cervical cancer (UCC), breast carcinoma (BC), ovarian cancer (OC) and endometrial cancer (EC) (P<0.01).
  • [MeSH-minor] Angiopoietin-2 / biosynthesis. Angiopoietin-2 / genetics. Argonaute Proteins. Biomarkers, Tumor / analysis. Cell Line, Tumor. Female. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. Receptor, TIE-2 / biosynthesis. Receptor, TIE-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204292.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Argonaute Proteins; 0 / Biomarkers, Tumor; 0 / PIWIL1 protein, human; 0 / Proteins; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


79. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Serum amyloid A: a novel biomarker for endometrial cancer. Cancer; 2010 Feb 15;116(4):843-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum amyloid A: a novel biomarker for endometrial cancer.
  • BACKGROUND: The authors investigated the expression of serum amyloid A (SAA) in endometrial endometrioid carcinoma and evaluated its potential as a serum biomarker.
  • METHODS: SAA gene and protein expression levels were evaluated in endometrial endometrioid carcinoma and normal endometrial tissues, by real-time polymerase chain reaction (PCR), immunohistochemistry (IHC), and flow cytometry.
  • SAA concentration in 194 serum samples from 50 healthy women, 42 women with benign diseases, and 102 patients including 49 grade 1, 38 grade 2, and 15 grade 3 endometrial endometrioid carcinoma was also studied by a sensitive bead-based immunoassay.
  • RESULTS: SAA gene expression levels were significantly higher in endometrial endometrioid carcinoma when compared with normal endometrial tissues (mean copy number by real-time PCR = 182 vs 1.9; P = .001).
  • IHC revealed diffuse cytoplasmic SAA protein staining in poorly differentiated endometrial endometrioid carcinoma tissues.
  • High intracellular levels of SAA were identified in primary endometrial endometrioid carcinoma cell lines evaluated by flow cytometry, and SAA was found to be actively secreted in vitro.
  • SAA concentrations (microg/mL) had medians of 6.0 in normal healthy women and 6.0 in patients with benign disease (P = .92).
  • In contrast, SAA values in the serum of endometrial endometrioid carcinoma patients had a median of 23.7, significantly higher than those of the healthy group (P = .001) and benign group (P = .001).
  • Patients harboring G3 endometrial endometrioid carcinoma were found to have SAA concentrations significantly higher than those of G1/G2 patients.
  • CONCLUSIONS: SAA is not only a liver-secreted protein, but is also an endometrial endometrioid carcinoma cell product.
  • SAA is expressed and actively secreted by G3 endometrial endometrioid carcinoma, and it is present in high concentration in the serum of endometrial endometrioid carcinoma patients.
  • SAA may represent a novel biomarker for endometrial endometrioid carcinoma to monitor disease recurrence and response to therapy.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Hematol. 2000 Jan;7(1):64-9 [10608507.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1090-6 [18021217.001]
  • [Cites] Proteomics. 2003 Sep;3(9):1720-4 [12973732.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):43-52 [14734450.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5293; author reply 5293-4 [15297433.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1204-9 [2220931.001]
  • [Cites] N Engl J Med. 1996 Aug 29;335(9):640-9 [8692240.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):441-7 [9277659.001]
  • [Cites] J Histochem Cytochem. 1998 Dec;46(12):1377-84 [9815279.001]
  • [Cites] Clin Chem Lab Med. 1999 Apr;37(4):381-8 [10369107.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1561-73 [15785748.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):63-73 [16116035.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):84-93 [17063306.001]
  • [Cites] Acta Obstet Gynecol Scand. 2006;85(12):1501-5 [17260229.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):768-73 [18682706.001]
  • [Cites] Am J Obstet Gynecol. 2000 Jun;182(6):1328-34 [10871446.001]
  • (PMID = 20041483.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122728-01A2; United States / NCI NIH HHS / CA / R01 CA122728-01A2; United States / NCI NIH HHS / CA / R01 CA122728; United States / NCI NIH HHS / CA / CA-16,359; United States / NCI NIH HHS / CA / P30 CA016359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Serum Amyloid A Protein
  • [Other-IDs] NLM/ NIHMS158487; NLM/ PMC2819580
  •  go-up   go-down


80. Haberal A, Cil AP, Gunes M, Cavusoglu D: Papillary adenofibroma of the cervix: a case report. Ultrasound Obstet Gynecol; 2005 Aug;26(2):186-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenofibroma is an extremely rare benign biphasic neoplasm that is classified into the mixed epithelial and mesenchymal tumor group.
  • It typically affects the endometrium, but may occur in the cervix or in an extrauterine location.
  • Preoperative diagnosis of this tumor is usually difficult.
  • This lesion appears to be clinically and histologically benign but must be differentiated from malignant lesions of the uterus, particularly from adenosarcoma, which can be suggestive of adenofibroma.
  • Accurate diagnosis of these benign tumors permits appropriate counseling of patients.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 16041681.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Xiong Y, Xiong YY, Zhou YF: [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):594-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 83 cases of endometrial hyperplasia were selected and reclassified according to EIN diagnostic criteria.
  • Expressions of beta-catenin, Glut-1 and PTEN proteins were investigated by immunohistochemistry in 10 proliferative endometrium, 83 endometrial hyperplasia and 24 endometrioid adenocarcinoma. RESULTS:.
  • (1) 24 EIN (28.9%) lesions were reclassified among 83 previously diagnosed endometrial hyperplasia, of which, 16 of 24 EIN cases (66.7%) had a prior diagnosis of complex atypical hyperplasia.
  • The relation between EIN diagnosis and grade of atypical hyperplasia was not obvious (P > 0.05). (2) Normal (membranous) expression of beta-catenin was present in 10 cases of proliferative endometrium.
  • Abnormal (marked membranous/cytoplasmic, cytoplasmic and/or nuclear or negative) expression rates of beta-catenin in EIN lesions (50%, 12/24) and endometrioid adenocarcinoma (66.7%, 16/24) were significantly higher than that of benign hyperplasia (10.2%, 6/59) respectively (P < 0.01).
  • However, the difference was not significant between EIN lesions and endometrioid adenocarcinomas (P > 0.05). (3) Low level expressions of Glut-1 was present in proliferative endometrium and benign hyperplasia.
  • Overexpression of Glut-1 was present in 58.3% (14/24) of EIN and 70.8% (17/24) of endometrioid adenocarcinoma, respectively, and statistically not significant (P > 0.05). (4) Percentages of loss of PTEN expression showed no difference between EIN lesions (37.5%, 9/24) and proliferative endometrium (2/10), benign hyperplasia (28.8%, 17/59), endometrioid adenocarcinoma (62.5%, 15/24; P > 0.05).
  • However, loss of PTEN expression in endometrioid adenocarcinoma was significantly higher than those in proliferative endometrium and benign hyperplasia (P < 0.05).
  • The expression of both markers may be useful in distinguishing a benign hyperplasia from EIN and endometrioid adenocarcinoma.
  • Lack of PTEN expression may be the earliest event in endometrial carcinogenesis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Glucose Transporter Type 1 / metabolism. PTEN Phosphohydrolase / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Hyperplasia / pathology. Female. Humans. Immunohistochemistry. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079187.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


82. DeBernardo RL, Littell RD, Luo H, Duska LR, Oliva E, Kirley SD, Lynch MP, Zukerberg LR, Rueda BR: Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo. Cancer Biol Ther; 2005 Jan;4(1):103-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo.
  • Loss of Cables expression is associated with a high incidence of endometrial hyperplasia and endometrial adenocarcinoma in humans.
  • The Cables mutant mouse develops endometrial hyperplasia and following exposure to chronic estrogen develops early endometrial adenocarcinoma.
  • (1) loss of Cables expression occurred in high grade endometrioid adenocarcinoma, uterine serous and clear cell carcinoma as observed in endometrial hyperplasia and low grade endometrial adenocarcinoma;.
  • (2) overexpression of Cables inhibited cell proliferation in endometrial cancer (EC) cells in vitro and in vivo; and (3) progesterone could regulate the expression of Cables mRNA.
  • Hyperplastic endometrium and low and high grade endometrioid adenocarcinoma showed loss of Cables expression when compared to benign control secretory endometrium.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Cell Proliferation. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Gene Expression Profiling
  • [MeSH-minor] Animals. Carrier Proteins. Cyclins. Female. Humans. Mice. Phosphoproteins. Receptors, Progesterone / physiology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662117.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA98333
  • [Publication-type] Clinical Conference; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CABLES1 protein, human; 0 / Carrier Proteins; 0 / Cyclins; 0 / Phosphoproteins; 0 / Receptors, Progesterone
  •  go-up   go-down


83. Dowdy SC, Mariani A, Reinholz MM, Keeney GL, Spelsberg TC, Podratz KC, Janknecht R: Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol; 2005 Feb;96(2):368-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer.
  • OBJECTIVE: We have shown that HER2/Neu may activate the Smad7 promoter in endometrial, ovarian, and breast cancer cell lines.
  • Elevated Smad7 levels could then antagonize the TGF-beta pathway, leading to a reduction in tumor surveillance and potential cancer formation.
  • Our aim was to determine if Smad7 was in fact overexpressed in endometrial cancers and whether Smad7 RNA levels correlated with tumor grade or clinical endpoints.
  • METHODS: Snap-frozen endometrial cancer specimens from 16 patients with grade 1 disease and 23 patients with grade 3 disease were obtained.
  • Additionally, the endometrium from 18 patients who underwent hysterectomy for benign indications was collected as a control.
  • CONCLUSION: Smad7 appears to be upregulated in endometrial cancers compared to normal endometrium.
  • Given that many endometrial cancers have been shown to be TGF-beta-unresponsive, Smad7 should be investigated as a potential target to restore TGF-beta responsiveness and limit tumor growth.
  • [MeSH-major] DNA-Binding Proteins / biosynthesis. Endometrial Neoplasms / metabolism. Trans-Activators / biosynthesis. Transforming Growth Factor beta / antagonists & inhibitors
  • [MeSH-minor] Cytoskeletal Proteins / biosynthesis. Female. Gene Expression. Humans. Middle Aged. Phosphorylation. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Receptor, ErbB-2 / biosynthesis. Smad2 Protein. Smad3 Protein. Smad7 Protein. beta Catenin

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661223.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085257; United States / NCI NIH HHS / CA / CA 085257
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / RNA, Neoplasm; 0 / SMAD2 protein, human; 0 / SMAD3 protein, human; 0 / SMAD7 protein, human; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / Smad7 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta; 0 / beta Catenin; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


84. Hachisuga T, Emoto M, Kawarabayashi T, Kamihara Y, Nabeshima K: Endometrial cytologic findings in tamoxifen-treated breast cancer patients. Acta Cytol; 2009 Jan-Feb;53(1):24-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cytologic findings in tamoxifen-treated breast cancer patients.
  • OBJECTIVE: To describe the endometrial cytologic findings in tamoxifen (TAM)-treated patients and evaluate the clinical significance of these findings.
  • STUDY DESIGN: A total of 1,739 endometrial cytologic samples were obtained from 203 breast cancer patients with TAM treatment using an endocyte device.
  • Histologic examinations were recommended for the 23 endometrial cytologic samples (18 initial and 5 follow-up endometrial cytologic samples).
  • RESULTS: A large nuclear dimension and anisokaryosis of the endometrial glandular cells were found in the 23 endometrial cytologic samples.
  • All patients were amenorrheic and postmenopausal except for 3 premenopausal women with endometrial cancer.
  • The subsequent histologic examinations showed 3 atrophic endometria, 3 cystic atrophies, 11 endometrial polyps and 6 endometrial cancers.
  • The tumor diathesis and atypical features of cell aggregates, such as a loss of polarity and severe piling up of nuclei, were seen in the cytologic samples of the endometrial cancers but were not found in those with benign conditions.
  • CONCLUSION: A large nuclear dimension and anisokaryosis of the glandular cells were sometimes found in endometrial cytologic samples from the TAM-treated patients.
  • [MeSH-major] Breast Neoplasms / drug therapy. Endometrium / pathology. Tamoxifen / therapeutic use. Uterine Diseases / diagnosis


85. Fujiwaki R, Ohnuma H, Miura H, Sawada K: Uterine lipoleiomyoma in an elderly patient: a case report. Arch Gynecol Obstet; 2008 May;277(5):471-4
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Uterine lipoleiomyoma is a rare, fat-containing, benign tumor.
  • The clinical features and optimal treatment of this tumor remain unclear.
  • Magnetic resonance imaging demonstrated a uterine tumor with inhomogeneously high signal intensity.
  • Hysteroscopy revealed no abnormal findings in the endometrium.
  • She underwent a simple total abdominal hysterectomy, with a preoperative diagnosis of uterine liposarcoma.
  • CONCLUSION: In cases where the radiological appearance of a uterine tumor in an elderly patient is suspicious for liposarcoma, the possibility of a benign lipoleiomyoma should be considered.
  • [MeSH-major] Leiomyoma / diagnosis. Lipoma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Fatal Outcome. Female. Humans. Liposarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987306.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Ashton-Sager A, Paulino AF, Afify AM: GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol; 2006 Jun;14(2):187-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma.
  • Although the aberrant expression of GLUT-1 has been reported in a wide spectrum of epithelial malignancies, its possible correlation with the malignant transformation of endometrial epithelium has not been clearly established.
  • The purpose of this study was to evaluate the extent to which benign, hyperplastic, atypical, and malignant endometrial epithelia express GLUT-1.
  • The authors examined the IHC expression of GLUT-1 in cases of proliferative endometrium (n=12), secretory endometrium (n=10), endometrial polyps (n=10), adenomyosis (n=18), simple hyperplasia (n=14), complex hyperplasia without atypia (n=17), complex hyperplasia with atypia (n=17), and adenocarcinoma (n=31).
  • All cases from proliferative endometrium, secretory endometrium, adenomyosis, and simple hyperplasia and 90% (9/10 cases) of the endometrial polyps were negative for GLUT-1.
  • GLUT-1 positivity increased in intensity as the distance of tumor cells to stroma increased.
  • The authors conclude that GLUT-1 is preferentially expressed in complex hyperplasia with atypia and in adenocarcinoma and that GLUT-1 immunostaining is useful in distinguishing benign hyperplasia from hyperplasia strongly associated with malignancy.
  • GLUT-1-mediated glucose transport may allow hypoxic tumor cells distant from stromal blood vessels to survive through glycolysis.
  • These data suggest that the expression of GLUT-1 transporter may be closely related to the malignant transformation of epithelial endometrial tumors by supporting their increased need for glucose metabolism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785788.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1
  •  go-up   go-down


87. Rizkalla HF, Higgins M, Kelehan P, O'Herlihy C: Pathological findings associated with the presence of a mirena intrauterine system at hysterectomy. Int J Gynecol Pathol; 2008 Jan;27(1):74-8
Hazardous Substances Data Bank. LEVONORGESTREL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most women (60%) had the expected appearance of atrophy of the endometrial glands and pseudodecidual stromal reaction.
  • Thirty hysterectomy specimens contained benign leiomyomata with associated reduced reactivity in the uterine cavity and incomplete suppression of the endometrium.
  • In addition to leiomyomas, 1 specimen had an atypical polypoid adenomyoma and 1 had a benign adenomatoid tumor.
  • Two specimens had endometrial hyperplasia for which the IUS was unsuccessful in controlling bleeding.
  • [MeSH-minor] Endometrial Hyperplasia / complications. Endometrial Hyperplasia / pathology. Endometriosis / complications. Endometriosis / pathology. Female. Humans. Hysterectomy. Leiomyoma / complications. Leiomyoma / pathology. Retrospective Studies. Treatment Failure. Uterine Neoplasms / complications. Uterine Neoplasms / pathology


88. Mittal K: Distinguishing mucinous adenocarcinoma of the endometrium from benign endocervical epithelium. Int J Gynecol Pathol; 2009 Sep;28(5):479
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing mucinous adenocarcinoma of the endometrium from benign endocervical epithelium.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / analysis. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Jul;29(4):402-3 [20567157.001]
  • [CommentOn] Int J Gynecol Pathol. 2008 Oct;27(4):547-54 [18753965.001]
  • (PMID = 19696620.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


89. Gulati A, Kaushik R, Sharma J: Sclerosing stromal tumor of the ovary associated with benign endometrioid peritoneal implants. Indian J Pathol Microbiol; 2009 Oct-Dec;52(4):594-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing stromal tumor of the ovary associated with benign endometrioid peritoneal implants.
  • [MeSH-major] Choristoma / pathology. Endometrial Stromal Tumors / complications. Endometrial Stromal Tumors / diagnosis. Endometrium / pathology. Ovarian Neoplasms / complications. Ovarian Neoplasms / diagnosis. Peritoneum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805994.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down






Advertisement